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I. ABSTRACT
Experimental data provide strong evidence for the effective inhibition of tumorigenesis by 
isothiocyanates (ITCs), enzymatic cleavage products of glucosinolates in Brassica
vegetables like e.g. cabbage, broccoli or brussel sprouts. A number of ITCs have been 
identified as strong inhibitors of cell proliferation and apoptosis inducing agents which 
presents the chance for therapeutic impact of ITC-treatment on malignant transformed 
cells. Although much is known about ITC-induced apoptosis, many questions remain to be 
answered. The present study aimed to investigate the chemopreventive properties of 4-
methlythiobutylisothiocyanate (MTBITC), which are still largely unknown despite its 
substantial quantitative presence in food plants. Thereby, this study focused on the 
hypothesis that p53-dependent induction of apoptosis leads to suppression of telomerase. 
Human telomerase is stably expressed in the majority of cancer cells but absent in normal 
tissues which outlines the importance of this enzyme and its compounds in the process of 
carcinogenesis and provides a promising target for a selective therapeutic approach of 
malignancies. Proof of a connection between telomerase regulation and the induction of 
apoptosis by ITCs would present an important detail for a better understanding of the 
chemotherapeutic properties of these compounds. 
As a result, this study showed for the first time the suppression of the telomerase catalytic 
subunit hTERT and the holenzyme activity in malignant transformed cells mediated by an 
ITC. This was accompanied by a G2/M phase arrest of the cell cycle and apoptosis 
induction observed by internucleosomal DNA fragmentation, flow cytometry analysis and 
the detection of single stranded apoptotic DNA. A collapse of the mitochondrial membrane 
potential, as analysed by flow cytometry with the probe JC-1 and the suppression of the 
anti-apoptotic multi-domain Bcl-2 protein BclxL, were preceeded by glutathione depletion. 
Thereby, DNA strand breakage, induced by MTBITC-treatment probably presented the 
initial step in the growth suppression machinery. This DNA damage was followed by an 
increase in the protein level of the tumor suppressor p53 and subsequent by the 
initialization of p21WAF1 protein expression. But also, the activation of p63 expression by 
MTBITC-treatment could be shown for the first time. As a conclusion, the present findings 
support the idea of an existing extra-telomeric, cell cycle regulation function of telomerase 
in HepG2 cells. The results of this study also showed that irrespective of the intense 
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degradation kinetics of MTBITC, the strong cytostatic effect of the ITC was not markedly 
affected by it and suggests that although ITCs are only present at maximum concentrations 
in a living system for a rather short time, this might be sufficient to exert their therapeutic 
effects. 
I. ZUSAMMENFASSUNG
Die Inhibition der Tumorigenese durch Isothiocyanate (ITC), enzymatische 
Abbauprodukte von Glucosinolaten in Brassica-Gemüsen wie z. B. Kohl, Brokkoli oder 
Rosenkohl, ist durch experimentelle Daten belegt. Eine Reihe an ITC wurde als 
Wachstumsinhibitoren und Apoptose-induzierende Stoffe identifiziert, was die 
Möglichkeit eines Therapieansatzes bei maligne-transformierten Zellen durch ITC birgt. 
Obwohl bereits einiges über ITC-vermittelte Apoptose bekannt ist, bleiben noch viele 
Fragen offen. Die vorliegende Studie zielte darauf ab, die chemopräventiven Eigenschaften 
von 4-Methylthiobutyl isothiocyanat (MTBITC) zu untersuchen, welche noch größtenteils 
unbekannt sind, trotz der beachtlichen Quantität von MTBITC in Lebensmittelpflanzen. 
Dabei fokussierte diese Studie auf die Hypothese, dass p53-vermittelte Apoptoseinduktion 
eine Inhibition der Telomerase zur Folge hat. Humane Telomerase wird in den meisten 
Krebszellen stabil exprimiert, ist aber in normalen Geweben nicht detektierbar, was die 
Bedeutung dieses Enzyms und seiner Komponenten in der Karzinogenese hervorhebt und 
ein vielversprechendes Ziel für einen selektiven therapeutischen Ansatz bei malignen 
Tumoren darstellt. Der Beweis einer Verbindung zwischen Telomeraseregulation und der 
Apoptoseinduktion durch ITC würde ein wichtiges Detail für ein besseres Verständnis der 
chemotherapeutischen Eigenschaften dieser Stoffe darstellen. 
Als Ergebnis der hier vorliegen Studie konnte zum ersten Mal die Unterdrückung der 
katalytischen Untereinheit der Telomerase hTERT und der enzymatischen Aktivität durch 
ITC-Behandlung in malignen Zellen gezeigt werden. Dieser Effekt wurde begleitet von 
einem Zellzyklusarrest in der G2/M-Phase und Apoptoseinduktion, nachgewiesen durch 
internukleosomale DNA-Fragmentierung, durchflusszytometrische Analyse und der 
Detektion von apoptotischer Einzelstrang-DNA. Dem Zusammenbruch des 
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mitochondrialen Membranpotenzials, durchflusszytometrisch analysiert mittels JC-1, und 
der Unterdrückung des anti-apoptotischen multi-Domänen Bcl-2-Proteins BclXL ging eine 
Absenkung des Glutathionspiegels voran. Dabei stellen die durch MTBITC verursachten 
DNA-Strangbrüche vermutlich den initialen Schritt in der Proliferationsinhibition dar. 
Diese DNA-Schäden waren von einem Anstieg des Tumorsuppressor p53-Proteins 
begleitet und im Folgenden von der Initialisierung der p21WAF1-Expression. Zum ersten 
Mal konnte hier auch die Aktivierung der Expression des p63-Proteins durch MTBITC-
Behandlung gezeigt werden. Schlussfolgernd unterstützen die vorliegenden Ergebnisse das 
Konzept einer existierenden extra-telomeren, Zellzyklus-regulierenden Funktion der 
Telomerase in HepG2-Zellen. Die Ergebnisse dieser Untersuchung zeigen auch, dass 
ungeachtet der rapiden Degradation von MTBITC im untersuchen in vitro-Modell, die 
starken zytostatischen Effekte des ITCs auf die Zellkultur nicht merklich betroffen waren. 
Dies deutet darauf hin, dass obwohl nachgewiesener Weise ITC nur für relativ kurze Zeit
Maximalkonzentrationen in vivo erreichen, dies dennoch ausreichend sein kann, um einen 
therapeutischen Effekt auszuüben.  
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II. INTRODUCTION
2.1 ITCs in Disease and Cancer Prevention
A number of studies support the assumption that isothiocyanates (ITCs) affect the risk of 
developing chronic diseases such as cancer (Bianchini and Vainio, 2004; Conaway et al., 
2002; Hecht, 1999). These sulphur-containing metabolites have been identified as the 
agents responsible for lowering cancer risk in people eating diets rich in cruciferous 
vegetables and have therefore recently attracted intense research interest. The association 
between cancer risk and brassica vegetable consumption derived from cohort, as well as 
case-control studies, have been summarized in large part by van Poppel and co-workers 
(van Poppel et al., 1999). 
Approximately 120 individual glucosinolates (GLSs) - the glucopuranose-containing 
precursor products of ITCs - have been isolated chiefly from species of the family 
Brassicaceae and allied families (Fahey et al., 2001). The ITCs are formed by myrosinase-
derived hydrolysis of GLSs, following cell damage by chewing, cutting, or processing the 
vegetable (Holst and Williamson, 2004). Despite the great variety of structure homologues 
so far, experimental research on the cancer preventive properties of ITCs limit to only a 
fractional number thereof.
2.2 4-Methylthiobutylisothiocyanate (MTBITC)
The ITC 4-methylthiobutylisothiocyanate (MTBITC, erucin) was fist characterized in 
steam volatile oils of brassica vegetables by Buttery and co-workers in 1976 (Buttery et al., 
1976). It has been detected in a large number of brassica vegetables, and is present in 
considerable amounts in these plants as shown by Zeuner (Zeuner, 2005). However, it is 
only recently that its chemopreventive properties have been addressed, dealing with the 
cytostatic features of this ITC in human leukaemia cells (Fimognari et al., 2004a; 
Fimognari et al., 2004b). MTBITC is particularly of interest, not only because of its 
quantitative presence in plants, but because it has been shown that sulforaphane (SFN), 
which has been extensively studied and is one of the most potent chemopreventive ITC 
known to date, is oxidized in vivo to its structure analogue MTBITC (Kassahun et al., 
1997). In their study, 12 % of the NAT-conjugate of MTBITC was recovered in rats 
treated with SFN and 67 % of a SFN-metabolite was detected in animals administered 
MTBITC. These findings provoke a closer look at the bioactivity of MTBITC. 
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2.3 Chemopreventive properties of ITCs
The cancer chemopreventive (i.e. prophylactic and therapeutic) activities of ITCs have 
been reviewed previously by Thornally (Thornalley, 2002). These include the tandem and 
cooperating inhibitory effects on phase I cytochrome P450 metabolizing enzymes 
(probably by a combination of enzyme suppression and direct inhibition of their catalytic 
activities, which thereby lowers the levels of ultimate carcinogens formed) and the 
enhanced expression of phase II enzymes. ITCs also contribute to the induction of 
multidrug resistance (MDR) transporters, which in consequence actively facilitate the 
secretion of xenobiotic compounds (Harris and Jeffery, 2007). But more than that, recently, 
a number of ITCs have been identified as strong inhibitors of cell proliferation and 
apoptosis inducing agents (Wu et al., 2005),which presents the chance for therapeutic
impact of ITC-treatment on malignant transformed cells. 
2.4 Apoptosis induction and cell cycle regulation by ITCs
Because of the structure analogy of ITCs, their mechanisms of apoptotic action are similar  
although the cell death pathway (intrinsic, extrinsic or both) at the least seems to be 
strongly dependent on the cell type (Keum et al., 2004). A majority of the studies have 
focused on the mitochondria-mediated intrinsic path of apoptosis induction by ITCs, which 
is initialized by an alteration in the mitochondrial membrane permeability and cytochrome 
c release into the cytoplasm. This release is mediated by mitochondrial membrane proteins 
of the Bcl-2 family, either acting pro-apoptotic (e.g. Bax, Bak, Bad) or anti-apoptotic (e.g. 
Bcl-2, BclxL). The subsequent recruitment and activation of caspase 9 leads to the cleavage 
of caspase 3 and internucleosomal DNA fragmentation. This process occurs under the 
premise of sufficient ATP to maintain the integrity of the cell and to provide the necessary 
energy for enzymatic degradation. An updated, more detailed description of the topic is 
provided by Zhang and his group (Zhang et al., 2006). Additionally to apoptosis-induction, 
ITCs have also been shown to arrest cell cycle progression at the G1, S or G2/M phase 
(Rose et al., 2003; Tang and Zhang, 2004; Zhang et al., 2003). Which outcome prevails is 
quite likely to depend on balancing signals from various sources. In a number of these 
systems, however, cell death induction could be observed in dependence to the p53 status 
in vitro and in vivo (Huang et al., 1998; Kuang and Chen, 2004).
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2.5 The p53 family
The p53 gene family is one of the most important tumor suppressor families known to date, 
inducing growth suppression or apoptosis, once activated. All three members (p53, p63 
and p73) share similar transcriptional functions, although their execution function has 
varying efficiency (Shimada et al., 1999). Regulation of the p53 protein occurs on both 
mRNA and protein level, whereas the murine double minute (MDM2) oncogene plays the 
most central role by conjugation of p53 with ubiquitin, which leads to its proteosomal 
degradation (Iwakuma and Lozano, 2003). A review on p53-dependent apoptosis pathways 
is provided by Shen et al. (Shen and White, 2001). p63 shares substantial structural and 
functional homology with p53, suggesting a comparable function as a tumor suppressor in 
human cancer. Unlike p53, p63 gives rise to multiple protein isoforms due to differential 
mRNA splicing and alternative promoter utilization. When overexpressed, p63 has been 
shown to bind p53 DNA target sites, transactivate p53-responsive genes and induce cell 
cycle arrest and apoptosis in mammalian cells in a p53-like manner (Calabro et al., 2002).
2.6 The relationship between telomeres, telomerase and p53
p53 plays a crucial role not only in the limitation of cellular proliferation by apoptosis 
induction or cell cycle arrest, but it has also been shown by several authors that p53 
transcriptionally suppresses the activation of human telomerase reverse transcriptase 
(hTERT) (Saito et al., 2004; Shats et al., 2004; Stampfer et al., 2003) suspecting a p53-
dependent regulatory path for hTERT control in human cells. 
hTERT presents the catalytic subunit of telomerase (Bryan et al., 1998), a 
ribonucleoprotein complex, consisting - besides hTERT - of an RNA template molecule 
(hTR) (Feng et al., 1995) and a number of telomerase associated proteins (Chang et al., 
2002; Smogorzewska and de Lange, 2004). Although hTR is constitutively expressed in all 
tissues, hTERT expression seems to be restricted to telomerase-positive tissue, indicating 
that hTERT is the limiting factor for the enzyme activity (Bodnar et al., 1998). A positive 
correlation has been found by several authors between the amount of hTERT mRNA and 
the enzymatic activity of telomerase, suggesting that the enzyme activity is regulated 
directly at the gene transcriptional level of hTERT (Cong et al., 1999; Ducrest et al., 2002; 
Yi et al., 1999). The hTERT gene possesses two p53 binding motifs upstream of the 5`core 
promotor region at –1877 and –1240 relative to the start of transcription. The binding of 
stabilized p53 with the assistance of the transcription factor SP1 at these two motifs of 
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hTERT represses the hTERT promotor (Kanaya et al., 2000). Besides this, regulation of 
telomerase occurs on the level of posttranslational protein-protein interaction and protein-
phosphorylation. Recently, the heat shock protein 90 (HSP90) chaperon complex has been 
demonstrated to bind to hTERT and contribute in a large part to the holenzyme activity 
(Akalin et al., 2001). A proposed model suggests that both HSP90 and p23 bind to hTERT 
and influence proper assembly with hTR to form the active enzyme (Forsythe et al., 2001).
In consideration of the fact that hTERT is primarily nuclear and HSP90 is prevalent in the 
cytoplasm, it has been proposed that telomerase assembly occurs in the nucleus or that –in 
contrast to other chaperone targets- HSP90 remains associated with the functional enzyme. 
Telomerase is continuously repressed in most normal somatic tissues, except for stem and 
germ cells. In contrast to this, 80 to 90 % of cancer cells stably express this enzyme (Shay 
and Bacchetti, 1997), which is reactivated during malignant transformation. This 
(re)activation provides unlimited proliferation capacity for the tumor cells by de novo
synthesis of telomeric (TTAGGG)n sequences, circumventing the “end-replication 
problem” of DNA synthesis (Kim et al., 1994; Smogorzewska and de Lange, 2004).
Telomerase activity has been shown to be strongly correlated with the state of malignancy 
in transformed cells and is discussed as a useful molecular marker in the prognosis of 
cancer (Triginelli et al., 2006; Zhang et al., 1999). Moreover, its reactivation in most 
human cancers outlines the importance of this enzyme and its subunits in the process of 
carcinogenesis and provides a promising target for a selective therapeutic approach to 
malignancies.
Only recently, it has been found that telomerase exerts extra-telomeric effects (Perrault et 
al., 2005). Besides the catalytic function of hTERT, it directly takes part in protecting the 
chromosome ends from signalling into cell cycle arrest and/or apoptosis (Blackburn, 
2000). Telomeres form a higher order t-loop structure, with their 5´overhangs invading and 
being buried in-between double stranded telomeres and hTERT is critical for maintaining 
the capping of telomeres (Griffith et al., 1999). The loss of this capping function would 
generate one or more free telomere ends. This could lead to end-to-end fusions and 
degradation of chromosomes, which in consequence could be recognized by specific DNA-
damage sensors, including p53. A chemical-induced rapid degradation of the telomeric 
repeats triggering apoptotic death has been described in several systems (Ramirez et al., 
2003). Recent studies by Cao and co-workers (Cao et al., 2002) discovered that hTERT 
owns a similar subcellular distribution pattern as p53 throughout mitosis suggesting the 
possibility, that hTERT and p53 cooperate to maintain normal mitotic spindle function 
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during chromosome segregation. Thereby, hTERT starts to dissociate from chromosomes 
in the mitotic prophase and binds successively to microtubule spindles at metaphase. In 
anaphase, hTERT finally localizes around the daughter chromatids.  The precise 
mechanism of this extra-telomeric function however is under current research and needs to 
be refined and further detailed.
2.7 Objectives and hypothesis
As described above, the impairment of cell growth by specific hTERT targeting can be 
sustained by two pathways. First, successive telomere shortening as a result of prolonged 
inhibition of the telomerase enzyme activity. This process requires a period of several 
months, depending on the proliferation rate of a cell, finally leading into cellular
senescence. The second pathway comprises the loss of the hTERT-mediated capping 
function of telomerase which results in the initialization of apoptotic signalling. 
The present study aimed to test the hypothesis that p53-dependent induction of apoptosis, 
mediated by ITCs, leads to suppression of telomerase in a human malignant transformed 
cell line. This was investigated in the human hepatoma HepG2 cell line, a wildtype p53 
cell line with strong telomerase activity and short telomeres. Since ITCs are metabolized in 
vivo mainly by phase I and II enzymes to their mercapturic acid-derivatives in the liver, 
this cell line qualified for the question at issue. 4-methylthiobutyl-ITC was exemplarily 
tested for this hypothesis. MTBITC was especially interesting due to its substantial 
quantitative presence in food plants and the fact that its chemopreventive properties are 
largely unknown. Although much is known about ITC-induced apoptosis, many questions 
remain to be answered. Proof of a connection between telomerase and the induction of 
apoptosis by ITCs would present an important detail for better understanding of the 
chemotherapeutic properties of these compounds in human-derived cells. 
In detail, the following aims were addressed:
 to investigate the effects of MTBITC on the proliferation of HepG2 cells and to 
characterize the apoptotic origin
 to determine the role of p53 family members in programmed cell death
 to analyse the influence of MTBITC on telomerase and telomere length
 to determine cofounders of the observed findings
 to investigate the stability and degradation kinetics of MTBITC in the applied 
system
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III. MATERIAL 
3.1 The human cell culture model HepG2
A large part of the studies dealing with the p53-dependent regulation of telomerase have 
been carried out with non-physiological overexpression of p53 or have lacked isogenic 
controls (Lin and Elledge, 2003). In contrast to this, in the present work, the experiments 
were carried out with the human derived hepatoma cell line HepG2, a hepatocellular 
carcinoma (HCC) cell line expressing physiological levels of p53. HepG2 are a telomerase 
positive cell line with rather short telomeres of around 5.6 kb in length (Furuta et al., 
2003). They were originally derived in 1979 from an 11-year old Argentine boy (Aden et 
al., 1979), with the intention of replacing fresh human hepatocytes in early toxicology 
screening. This cell line has been successfully cultured for more than 100 passages (Silvers 
et al., 1994).
Figure 1: HepG2 cells in different growth states: a) 24 hours, b) 3 days and c) 6 days after seeding
3.1.1 Biochemical characterization
HepG2 cells are considered to be suitable in vitro models of the HCC since they have been 
shown to possess similar characteristics typical for primary hepatocytes. Under cell culture 
conditions, they secrete most of the plasma proteins, like e.g. fibrinogen and albumin as 
well as apolipoproteins (Knowles et al., 1980). HepG2 cells also exhibit carrier-mediated 
bile acid uptake, functionally resembling the multispecific organic anion transporting 
polypeptide (OATP) of the human liver (Kullak-Ublick et al., 1996). But more interesting 
is the fact that they express considerate levels of Phase III transporters, including the 
c)a) b) c)
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multidrug resistance proteins MRP1, MRP2 and the P- glycoprotein P-gp (Harris and 
Jeffery, 2007).
The successful application of HepG2 cells in genetic toxicology is mainly based on the 
capability of the cells to synthesize enzymes of the xenobiotica metabolism, reflecting the 
metabolism of normal human hepatocytes (Hewitt and Hewitt, 2004; Wilkening and Bader, 
2003; Wilkening et al., 2003). This is in advantage to cells which have to be externally 
supplemented with these enzymes (e. g. by the addition of arochlor induced S9-mix from 
rats) for activation of promutagens or –carcinogens (Doostdar et al., 1993; Knasmuller et 
al., 1998).
3.1.2 Tumor suppressor gene product p53 status 
The tumor suppressor gene p53 is located on the short arm of chromosome 17 and is 
known to be frequently deleted and abnormally expressed in several HCC derived cell 
lines (Hosono et al., 1991). For the HepG2 cell line, however, several groups have shown a 
normal wildtype (wt) expression of p53 (Puisieux et al., 1993). The mRNA level and 
protein level of p53 have been reported as normal with a half-life of the p53 protein in this 
cell line to be less than 30 min. (Bressac et al., 1990; Puisieux et al., 1993).
3.2 General material 
For cell culture technique, immunoblotting, sterile filtration of chemicals and GC-MS/MS 
analysis, the following materials shown in table 1 were used:
Table 1: Materials used for cell culture, sterile filtration, immunoblotting and GC-MS/MS analysis 
Material Cat. No. Distributor
96-well plate, non-sterile, transparent 32409522 Greiner bio-one
96-well plate, sterile 655180 Greiner bio-one
cell culture flask 025 cm2 with 0.22 μM filter cap 831810002 Sarstaedt
cell culture flask 075 cm2 with 0.22 μM filter cap 658.175 Sarstaedt
cell culture flask 175 cm2 with 0.22 μM filter cap 831.812.002 Sarstaedt
cell scraper 541070 Greiner bio-one
centrifuge conical tubes, PA 16 x 51 mm, 5.5 ml vol 358122 Beckman Instruments 
Hyperfilm ECL, 18 x 24 cm RPN3103K Amersham Bioscience
Hyperfilmcassette, 18 x 24 cm RPN13642 Amersham Bioscience
Millex FG (PTFE) Syringe driven filter unit, 0.2 μm SLFG025LS Millipore
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Millex GP Syringe driven filter unit, 0.22 μm SLGP033RS Millipore
Nescofilm 2569.1 Roth
nitrocellulose membrane, hybond ECL RPN 3103K Amersham Bioscience
Sterile filter (bottle top) SCGPT02RE Millipore
syringe, singel use, sterile 0.8 x 40 mm REF304432 Becton Dickenson
whatmanpaper, 17CVR, 46 x 57 cm 3017915 Whatman Internat. Inc.
11 mm crmp cp alum PTFE 392611627 Varian
Crimp Top wide opening vial 2 ml 12 x 32 mm glass 392611635 Varian
Microliter syringe 10 μl Syrc L10-26 S-AS Hamilton 
3.3 Chemicals
Standard chemicals were obtained from the Sigma-Aldrich Group (Taufkrichen), Serva 
(Heidelberg), Lifetechnologies (Karlsruhe) and Merck (Darmstadt). In addition, the 
following alphabetically arranged chemicals shown  in table 2 were used:
Table 2: Chemicals used for the experiments and their specifications
Chemicals Purity Cat. No. Distributor
2-Mercapto-Ethanol > 98 % 805740 Merck
2-Propanol 99.5 % 8067 J. T. Baker
Aceton > 99.9 % 1.000.14.2500 Merck
Acrylamide solution, 30 % (37,5:1) A3626,0250 Applichem
Agarose for electrophoresis 11404 Serva
Developer G138i A+B+C Agfa
Rapid Fixer G334i A+B Agfa
Ammoniumpersulfat A9164 Sigma-Aldrich
Boric acid p. a. 1.001.651.000 Merck
Cyclohexane for synthesis 8.222.68.2500 Merck
DEPC K028.3 Roth
Digitonin D141 Sigma-Aldrich
Dimethylsulfoxide (DMSO) cell culture grade A3672,0100 Applichem
Dithriothreitol (DTT) 99% D-9779 Sigma-Aldrich
D-Mannitol M9546 Sigma-Aldrich
Dodecylsulfat-Na-Salt (SDS) 20760 Serva
EDTA disodium salt dihydrate p.a. 8043.2 Roth
Ethanol p. a. 32205 Riedel-de-Haen
Ethylacetate for synthesis 8.222.772.500 Merck
Glycerol p.a. 3783.1 Roth
Glycin 10.670.500 Applichem
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Glyzin A1377.5000 Applichem
Hydrochloric acid fuming 37% 1.003.171.000 Merck
Maleic acid 63190 Sigma-Aldrich
Metaphosphoric acid M6288 Sigma-Aldrich
Methanol p.a. 65543 Fluka
Sodium chloride 3957.2 Roth
Sodium hydroxide 6771.1 Roth
Sucrose 99 + % S-0389 Sigma-Aldrich
TEMED > 99 % 2367.3 Roth
Triethanolamine T5,830-0 Sigma-Aldrich
Tris 99.9 % 4855.2 Roth
Triton X-100 1.086.431.000 Merck
Tween 20 for electrophoresis P5927 Sigma-Aldrich
3.4 Cell culture reagents
For culture of the HepG2 and CCRF-CEM cell line the reagents in table 3 were utilized. 
All cell culture reagents were sterile filtered (0.2 μm). The medium for HepG2 cells 
consisted of DMEM, supplemented with 15 % FCS and 50 μg/ml gentamycin; for culture 
of CCRF-CEM cells, RPMI medium containing 10 % FCS was used. The prepared media 
were stored at 4 °C and pre-warmed to 37°C before use. 
Table 3: Reagents for the culture of the HepG2 and CCRF-CEM cell line
Cell Culture Reagents Cat. No. Distributor
DMEM low Glucose (1 g/l) with L-Glutamin E15-806 PAA
DMEM w/o phenol red 11880 Invitrogen
Dulbeccos PBS w/o Ca2+/Mg2+ H15-002 PAA
Fetal calf serum (FCS), Gold A15-649 PAA
Gentamycin solution (50 mg/ml) 47991.01 Serva
L-Glutamine 200 mM M11-004 PAA
RPMI w/o L-glutamine E15-039 PAA
Trypsin, 2.5 % (10 x) in PBS L 11-001 PAA
3.5 Antibodies 
The antibodies for immunoblotting experiments are listed in table 4,. Primary antibodies 
were derived from immunized mice or rabbits, the secondary HRP-labelled IgG antibodies 
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were derived from goat or horse. The antibodies were purchased as ready made solutions 
and applied at the given dilution factor in the immunoblotting experiments.
Table 4: Primary and secondary antibodies
Antibody Source Specificity Dilution factor Cat. No. Distributor
b-Actin (AC-74) mouse monoclonal Ab 1:3000 A 5316 sigma
Bcl-xL rabbit monoclonal Ab 1:500 2762 cell signalling
HSP70 rabbit polyclonal Ab 1:1000 4872 cell signalling
HSP90 rabbit polyclonal Ab 1:1000 4874 cell signalling
hTERT (C-term) rabbit monoclonal Ab 1:500 1531-1 epitomics
MDM2 (D-12) mouse monoclonal Ab 1:100 sc-5304 santa cruz
p21 Waf1/cip1 (DCS60) mouse monoclonal Ab 1:500 2946 cell signalling
p53 (BP53-12) mouse monoclonal Ab 1:2000 P 5813 sigma
p63 (87C53) mouse monoclonal Ab 1:100 ab11995 abcam
Mouse IgG, HRP-linked goat 1:4000 7076 cell signalling
Rabbit IgG, HRP-linked horse 1 :4000 7074 cell signalling
3. 6 Electrophoresis reference bands
To monitor the progress of protein separation and transfer efficiency and for the 
identification of proteins in the polyacrylamide gels, the molecular weight marker listed in 
table 5 was used. Additionally, table 5 contains the DNA markers, applied to verify the 
size of the amplified telomerase fragments.
Table 5: Molecular weight markers for protein and DNA analysis
Chemicals Cat. No. Distributor
Precision Plus Protein Dual Color Standard 161-0374 Biorad
DNA Ladder 100 bp (0,1μg/μl) 12228692 Invitrogen
DNA Ladder, 50 bp (1 μg/μl) 10416-014 Invitrogen
3.7 Assay kits
For the assessment of cell proliferation, formation of single stranded apoptotic DNA, 
glutathione content of HepG2 cells, telomerase activity and telomere length determination, 
the kits in table 6 were used. 
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Table 6: Kits implemented in the investigations with HepG2 cells
Assy kits Cat. No. Distributor
Apoptosis Elisa Kit, ssDNA APT225 Chemicon
Cell Proliferation Reagent, WST 1 11644807001 Roche
Glutathione Assay Kit ALX850038-K101 Alexis
TeloTAGGG Kit 2013789 Roche
Telomere PNA Kit/FITC for flow cytometry K5327 Dako
3.8 Staining solutions
The staining solutions applied in the experiments are listed in table 7. 
Table 7: Staining solutions 
Chemical Cat. No. Distributor
Bradford Reagent B6916 Sigma-Aldrich
Dihydrorodamine (DHR123) D1054 Sigma-Aldrich
Erythrosin B 20096-4 Sigma-Aldrich
Ethidium bromide (10 mg/ml) E1510 Sigma-Aldrich
JC-1 T3168 Invitrogen
Propidium Iodide 81845 Fluka
SYBR Gold (10.000 x) S11494 Molecular Probes
3.9 Equipment and software
Besides the standard laboratory equipment, the following apparatus were used for the 
experiments:
 Infinite M 200 microplate reader, Tecan Group Ltd., Germany
 Geldocumentation Imager 2000, Intas, Germany
 High Performance Centrifuge Avanti J-30 I, Beckman Coulter,  Germany
 FACSCalibur with sorter, BD, Germany
           FSC Diode 488 nm 
           SSC PMT  488 nm  
           FL1 PMT   515-545 nm 
           FL2 PMT   564-606 nm 
           FL3 PMT        >650 nm
 Gas chromatograph CP-3800, coupled to a 1200 Quadrupole MS/MS, Varian, 
Germany
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           with a CombiPAL auto sampler and a factorFour fused silica capillary column
           (VF-35ms, 30 m x 0.25  mm (i.d.), 0.25 μm film  thickness, Varian, Germany
For data acquisition and analysis the following computer software was used:
 Gel-Pro Express 4.0, Intas, Germany (Densitomentric protein analysis) 
 Magellan 5.0, Tecan, Germany (Multiplate fluorescence and absorbance 
measurement and analysis)
 FACStation Software 3.5, BD, Germany (Flow cytometric data acquisition)
 Cellquest pro, BD, Germany (Flow cytometric data analysis)
 Modifit LT, Verity Software House Inc., UK (Flow cytometric data analysis)
 QuickCal 2.3, Bangs Laboratories, Inc., USA (Flow cytometric data analysis)
 Comet 5.5, Optilas, Germany (Assessment of DNA damage and data analysis)
 Analysis Macro 2000, Kinetic Imaging Ltd, UK (Assessment of DNA damage and 
data analysis)
3.10 Media, Buffers, Solutions
The buffers required for DNA laddering experiments are listed in table 8.
Table 8: Buffers and their chemical composition for the DNA laddering assay
Buffer/Solution Chemical/Solution
Weighted sample/
Volume Final concentration
TBE-buffer (10x) Tris 108 g 89 mM
Borsäure 55 g 89 mM
EDTA 9.3 g 0.05 M
Aqua dest. 1000 ml
Storage: RT 1-2 months
TE-buffer pH 8.0 Tris (1M) 10 ml 10 mM
EDTA 0.17 g 1 mM
Aqua dest. 990 ml
adjust pH with HCl
Storage: RT
TTE-buffer Triton X-100 100 μl 0.2 %
TE-buffer 50 ml
Storage: + 4°C
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DNA loading buffer bromophenol blue 1.25 % 1 ml
(10x) 0.5 M EDTA, pH 8,0 0.5 ml 50 mM
Glycerol 2.5 ml
Aqua dest. 1 ml
Storage: RT
Table 9 contains the compositions of the buffers and solutions needed for the conduction of 
the comet assay. 
Table 9: Buffers and their chemical composition for the comet assay
Buffer/Solution Chemical/Solution
Weighted sample/ 
Volume     Final concentration
LYSIS SOLUTION NaCl 146.1 g 2.5 M
(PH 10) EDTA 37.2 g 0.2 M
NaOH 8 g 0.2 M
Triton X-100 10 ml 1%
Aqua dest. 1000 ml
Storage: + 4°C for 
24 h
DNA UNWINDING NaOH 12 g 0.3 M
Aqua dest. 1000 ml
ELECTROPHORESIS NaOH 12 g 0.3 M
BUFFER (PH 13) EDTA 0.37 g 2 mM
Aqua dest. 1000 ml
NEUTRALISATION Tris 48.44 g 0.4 M
BUFFER (PH 7.5) Ajust pH with HCl
AGAROSE
normal melting 
point NMP 100 mg 1%
 NMP 70 mg 0.7 %
 LMP 50 mg 0.5 %
PBS w/o Ca2+, 
Mg2+ 10 ml, each
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The solutions and buffers prepared for the immunoblotting of proteins are listed in table 
10.
Table 10: Buffers and their chemical composition for immunoblotting of proteins
Buffer/Solution Chemical/Solution Weighted sample/ Volume
SDS stock solution SDS 10 % (w/v) 100 g
aqua dest. 1000 ml
Storage: RT
1.5 M Tris-HCl (pH 8.8) Tris 181.71 g
aqua dest. 1000 ml
adjust pH with HCl
Storage: RT
0.5 M Tris-HCl (pH 6.8) Tris 60.57 g
aqua dest. 1000 ml
adjust pH with HCl
Storage: RT
1 M Tris stock solution Tris 121.14 g
aqua dest. 1000 ml
Storage: RT
1.92 M Glycin stock solution Glyzin 144.13 g
aqua dest. 1000 ml
Storage: RT
electrophoresis buffer (10 x) Tris 30.3 g
pH 8.3 Glyzin 144 g
SDS (10%) 100 ml
aqua dest. 900 ml
Storage: + 4°C
APS solution (10 %) Ammoniumpersulphat (APS) 100 mg
aqua dest. 1 ml
Storage: + 4°C, for 24 h
Transfer buffer 1.92 M Glyzin 100 ml
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10 % SDS 2.5 ml
Methanol 200 ml
aqua dest. 672.5 ml
Storage: 4 hours
Tris based saline (TBS) (10 x) NaCl 80 g
aqua dest. 1000 ml
Storage: RT
Tris based saline (TBS) (1 x) Tween 20 1 ml
Storage: + 4°C, for 2 weeks
0.1 M Tris pH 8.6 Tris-HCl
Aqua dest. 1000 ml
Adjust pH with HCl
Storage: RT
Solution A 0.1 M Tris-HCl pH 8.6 200 ml
Luminol 50 mg
Storage: + 4°C, in the dark
Solution B p-hydroxycumaric acid 11 mg
DMSO 10 ml
Storage: RT, in the dark
3.11 Test substance and controls
 4-Methylthiobutylisothiocyanate (MTBITC, Erucin)
MTBITC (purity > 99.9 %) was synthesized by Prof. Dr. Schreiner, Dept. of Organic 
Chemistry, University of Giessen, Germany. The purity and specificity of MTBITC 
was verified by NMR and GC-MS/MS analysis.  MTBITC was dissolved in sterile 
DMSO and stored at –80°C. 
The following chemicals listed in table 11 were used for experimental setup and positive 
controls in the experiments.
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Table 11: Chemicals used for experimental setup and positive controls. The chemicals were either 
dissolved in DMSO or distilled water. 
Chemical Cat. No. Distributor/Source
Benzp(a)pyrene (> 97%) B-1760 Sigma-Aldrich
Camptothecin 1100 TOCRIS
hydrogen peroxide (30%) A 0626,025 Applichem
TMPyP4 (> 95%) 613560 Calbiochem
Valinomycin (> 98%) 94675 Fluka
 Dimethyl sulfoxide (DMSO)
As solvent control either dimethyl sulfoxide (DMSO) or distilled water were used. 
Both were sterile filtered before use. Since DMSO has been shown to be cytotoxic to 
complex mammalian cell systems, the effect of the solvent, especially on apoptosis 
induction and the mitochondrial membrane potential (MMP) of HepG2 cells was 
tested in preliminary experiments. No alteration of the test parameters could be 
detected at a concentration of 0.1 % DMSO, which was then used in all further 
experiments. Noticeably, in concentrations exceeding 0.3 %, alterations in ssDNA 
formation and an influence on the MMP occurred in the treated cultures. 
 Benzo(a)pyrene (B(a)P)
As positive control for the Comet Assay, the procarcinogen benzo(a)pyrene (B(a)P) 
was used at a final concentration of 100 μM. This five-ring PAH is classified by the 
IARC as a probable human carcinogen (2A) and is clearly positive mutagenic in short 
term assays with metabolic activation. B(a)P has been successfully applied as 
positive control in genotoxicity studies in the HepG2 model (Mersch-Sundermann et 
al., 2004).
 Camptothecin (CPT)
Exposure of cells to 6 μM CPT for 24 h was used as positive control in the apoptosis 
assays. This plant alkaloid indirectly causes apoptosis by binding to the enzyme 
topoisomerase I rendering cells to apoptosis induction by the formation of DNA 
single strand breaks (Capranico et al., 2007).
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 Hydrogen peroxide (H2O2)
The measurement of oxidative stress in HepG2 cells was done using 10 μM H2O2,
incubated for 1 h, as positive control. H2O2 has been successfully used earlier in 
studies investigating the usefulness of DHR123 as probe for ROS detection 
(Henderson and Chappell, 1993; Royall and Ischiropoulos, 1993). It does not react 
outside the cell with DHR123, but this reaction only takes place within peroxidase-
positive cells (Henderson and Chappell, 1993).
 TMPyP4
The cationic porphyrin TMPyP4 was used as positive control for telomerase 
measurement at a concentration of 300 μM. TMPyP4 is able to bind to and stabilize 
G-quadruplexes in human telomere sequences, resulting in the inhibition of 
telomerase activity (Grand et al., 2002).
 Valinomycin
The ionophore valinomycin was used at a concentration of 10 μM in flow cytometric 
analysis of the mitochondrial membrane potential (MMP). This macrocyclic 
dodecadepsipeptide possesses high specificity for potassium ions (K+) and facilitates 
the movement of K+ through lipid membranes leading to the breakdown of the 
mitochondrial membrane potential (Safiulina et al., 2006).
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IV. METHODS
4.1 General cell culture
HepG2 cells were supplemented with fresh culture medium every second to third day. The 
cells were passaged about once a week. All cell treatment steps described in this chapter 
were carried out with fluids pre-warmed to 37°C. 
4.1.1 Cryoconservation & reanimation of the cell culture
HepG2 cells were stored at minus 200°C in liquid nitrogen until use. For cryoconservation, 
the cells were harvested by trypsination, resuspended in culture medium and pelleted at 
700 g, 5 min., RT. The supernatant was decanted and 2 x 106 cells/ml resuspended in 1 ml 
of cryoconservation medium (DMEM containing 15 % FCS and 10 % DMSO). The cell 
suspension was transferred to a cryo cup and cooled at around 1 °C/min to minus 200°C.
For defrosting, the cells were put into a water bath at 37 °C and subsequently pelleted at 
700 g, 5 min, RT. The cells were washed twice with culture medium, resuspended in 5 ml 
fresh culture medium and transferred to a T25 culture flask for cultivation. 24 h later, the 
medium was refreshed to remove dead cells. 
4.1.2 Cell culture and passage
Subconfluent cell cultures were harvested by trypsination: adherent HepG2 cells were 
washed twice with PBS and incubated with a 0.1 % trypsin-EDTA-solution for 4 min at 
37°C. The enzymatic reaction was stopped with culture medium and the cell 
number/vitality determined by erythrosine B staining and counting in a Neubauer chamber. 
An appropriate amount was then transferred to a new culture flask and incubated in a cell 
culture incubator at standard conditions (95 % humidity, 5 % CO2, 37°C).
4.1.3 Procedure of chemical exposure
For chemical exposure, HepG2 cells were seeded in T25 culture flasks at a density of 1-2 x 
106 cells or 96 -well plates at a density of 1 x 104 cells. Exponential growing cells were 
then treated with the chemicals for the indicated time points.
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4.2 Assessment of cell proliferation and viability
Cytotoxicity can occur in the inner of a cell without disturbing the cellular membrane; 
therefore, a sensitive marker of enzymatic activity was used for the detection of cell 
growth. Cellular damage inevitably results in loss of the ability of the cell to maintain and 
provide energy for metabolic function and growth. This reduction in metabolic activity can 
be detected with the WST-1 assay. WST-1 is a tetrazolium salt which is cleaved to 
formazan by cellular enzymes. Recent studies support the assumption that WST-1 is 
reduced extra-cellular or at the plasma membrane by a mechanism involving superoxide 
(Berridge et al., 1996). An expansion in the number of viable cells results in an increase in 
the overall activity of mitochondrial dehydrogenases in the sample. This augmentation in 
enzyme activity leads to an increase in the amount of formazan dye formed, which directly 
correlates to the number of metabolically active cells in the culture. The formazan dye 
produced is then quantified by a scanning multiwell spectrophotometer (ELISA reader) by 
measuring the absorbance of the dye solution at 405 nm. 
The assay was carried out with a kit from Roche, according to the manufacturers´ 
instructions. The appropriate cell concentration and incubation time of WST-1 was 
determined in preliminary experiments. This was particularly of importance since the 
mitochondrial activity varies considerably between cell types and cell number. A 1 h-
incubation of cells with WST-1 resulted in the best signal intensity permitting the 
observation of a change in cell proliferation over 100 orders of magnitude. For further 
experiments, a number of 1 x 104 cells/100 μl were used. The assay was carried out three 
times in triplicate.
Figure 2: Kinetics of the 
metabolism of WST-1 in HepG2 
cells. The cells were grown at the 
indicated cell number for 24 h and 
then incubated with 10 μl WST-1 
for 0.5 to 4 h. Absorbance at 405 
nm (reference 620 nm) was 
determined in an ELISA reader. 
The bars represent the mean of 
three independent experiments ± 
standard deviation.
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4.3 Techniques for the assessment of apoptosis induction 
A first estimation of apoptosis induction by MTBITC was obtained with the DNA 
laddering assay, and the measurement of the “subG1” DNA content. For quantification of 
apoptosis induction and as a more specific marker, the ELISA-based detection of single 
stranded apoptotic DNA was carried out. The assessment of apoptosis induction with 
different methodologies is important for the verification of the results since the degree of 
DNA degradation to oligo- or mononucleosomal-size fragments does not always take place 
during apoptosis or varies in a broad range, depending on the stage and pathway of 
apoptosis, cell type and often the nature of the apoptosis-inducing agent. 
4.3.1 DNA degradation by internucleosomal fragmentation (DNA laddering)
During apoptosis, a series of morphological visible reorganisations occur in the cell: 
chromatin condensation, loss of cell volume and membrane blebbing. In parallel to that, 
DNA fragmentation occurs in the majority of cells, representing a biochemical hallmark of 
apoptosis. An endogenous Ca2+, Mg2+-dependent endonuclease is believed to be 
responsible for DNA cleavage, breaking double stranded DNA at internucleosomal sites 
(Golstein et al., 1991). Therefore, apoptotic DNA cleavage results in the formation of 
characteristic fragments of oligonucleosomal size (180-200 bp). This observation was first 
described by Wyllie (Wyllie, 1980). Qualitative determination of DNA fragmentation can 
be visualized by agarose gel electrophoresis analysis. Treated samples were harvested by 
scraping and washed twice with PBS before lysing with 600 μl of lysis buffer for 15 min 
on ice. Next, the cell debris was spun down by centrifugation at 15.000 g, 15 min, 4°C and 
the DNA- containing supernatant transferred to a 2 ml eppendorf cup. The solution was 
treated with 20 μl RNAse (Dnase free) for 1 h at 37°C and subsequently with 30 μl 
Proteinase K for another hour at 50°C. Then, the DNA was precipitated by addition of 600 
μl of 100 % 2-propanol and 20 μl of 5 M NaCl. A DNA pellet was derived by another 
centrifugation step (15.000g for 30 min at 4°C), the supernatant decanted and the DNA 
washed with 70 % ethanol. After decanting, the purified DNA pellet was dried for 10 min 
at RT and finally the DNA was dissolved in 50 μl TE Buffer, supplemented with loading 
buffer at a final concentration of 1 x and loaded onto a 2 %-agarose gel. 20 μg of a 100 bp 
marker were taken as reference for the laddering. The voltage was set to 50 V for 30 min 
and then set to 100 V for another 3 h. The detection of the ladder was carried out by 
staining of the gel with an ethidium bromide solution (10 μg/ml) for 20 min and 
subsequent detection under UV light.
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4.3.3 Measurement of the subG1 DNA content 
In a first approach to quantify apoptosis induction by MTBITC, the cellular DNA content 
was measured after permeabilization of HepG2 cells by fixation with 70 % ethanol. Since 
the alcohol fixation does not fully preserve highly degraded DNA within the apoptotic 
cells, this fraction of DNA leaks out during subsequent cell rinsing with aequous solutions. 
As a consequence, apoptotic cells containing only fractional DNA can be identified on a 
DNA content frequency histogram as cells being less stainable than G1 cells, the generally 
called “sub-G1” or “hypoploid” peak. (Gong et al., 1994; Kajstura et al., 2007). The 
threshold of DNA detection was set at a constant level of 1/10th to 1/20th of the 
fluorescence value of intact G1 cells. This methodology is proposed by Darzynkiewicz and 
co-workers (Darzynkiewicz et al., 2001) to eliminate all particles with a DNA content of 
less than 10 or 5 % of that of G1 cells from the analysis which might not be of apoptotic 
origin. HepG2 cells were seeded in T25 culture flasks at a density of 1 ×106 cells in 5 ml of 
culture medium. Exposure of the test substance MTBITC at a final concentration of 20 μM 
for 1-24 h was carried out at exponential growth. After test substance treatment, HepG2 
cells were harvested by trypsination, washed twice with PBS and subsequently fixed with 2 
ml of 70 % ice cold ethanol for 24 h at 4°C. After fixation, the cells were again washed 
with PBS two times, the cell pellet was subsequently resuspended in PI master mix (PBS, 
40 μg/ml propidium iodide, 100 μg/ml Rnase (Dnase free)) at a final density of 0.5×106
cells/ml and incubated for 30 min at 37 °C before analysis by flow cytometry in an FL-2 
histogram. Quantification of the “sub-G1” DNA peak was done with the software Modifit©
LT, UK. 
    M     C  TS1 TS2               C  TS3 TS4
Figure 3: Experimental setup of the DNA laddering 
assay by CPT-treatment of HepG2 cells. Induction of 
internucleosomal DNA fragmentation was detected after 
treatment of HepG2 cells with 6 μM CPT for 24 h. The 
fragmented DNA was separated in a 2 % agarose gel and 
stained with 10 μg/ml ethidium bromide. (M= DNA 100 
bp marker, C= a.d. treated cells; TS1 & TS3 = 2 x 106
cells, treated with CPT; TS2 & TS4 = 4 x 106 cells, 
treated with CPT. High salt alcoholic precipitation of 
DNA was conducted immediately (TS1 & TS2) or
overnight (TS3  & TS4). 
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4.3.5 Measurement of single stranded, formamide denatured apoptotic DNA (ssDNA 
assay)
It was shown in earlier studies that the staining of ssDNA with a monoclonal antibody is a 
sensitive and specific marker for the identification of apoptosis in adherent cells and is 
especially suitable to identify early stages of apoptosis (Frankfurt and Krishan, 2001a; 
Zhao et al., 2003). The monoclonal antibody used in this assay reacts with a homopolymer 
of deoxythimidine and requires a large stretch of at least 25-30 bases in length to bind to 
ssDNA. Therefore, the antibody does not react with single-stranded DNA ends, which is a 
great advantage compared to e. g. the TUNEL assay. Because it is this detection of ssDNA 
ends, present in necrotic cells, which is responsible for the non-specificity of the TUNEL 
assay. Additionally, under the applied gentle denaturation conditions i.e. heating to 75°C 
of formamide-treated samples, DNA denaturation neither occurs in necrotic nor in viable 
cells with DNA breaks, but only in the apoptotic cells (Allera et al., 1997). Changes in 
DNA-histone interactions in condensed chromatin of apoptotic nuclei are likely to be 
responsible for this effect. Whereas the phosphorylation of H3 results in tight chromatin 
condensation in mitotic nuclei, the deacetylation of H3 and H4 during apoptotic chromatin 
condensation decreases the affinity of histones to DNA, which is then readily denatured 
under these contitions (Frankfurt and Krishan, 2001b).
The assay was carried out as described by the manufacturer with slight modifications. 
Briefly, 1 x 104 cells were seeded into a 96-well plate and exposed to the test substance at 
exponential growth. After centrifugation of the plate (1000 g, 5 min. 4°C), the medium was 
removed and the cells fixed with 200 μl of 80 % methanol (30 min at RT) in the wells. The 
cells were attached to the plate surface by thorough drying at 37°C and the apoptotic DNA 
denatured by the addition of 50 μl of formamide for 10 min at RT and subsequent heating 
to 75°C for 20 min. The plate was cooled down, the formamide removed and the cells 
washed with PBS three times before adding 200 μl of 5 % nonfat dry milk for blocking of 
unspecific binding sites for 1 h at 37°C. The blocking solution was then substituted by 100 
μl of antibody solution consisting of a mixture of primary antibody and secondary enzyme-
conjugated antibody and incubated for another 30 min. Before the addition of ABTS 
solution for colour development, the cells were washed three times with the supplied 
washing solution for 30 s, each. The reaction was terminated by addition of an equal 
volume of stop solution (sulphuric acid) and the absorption detected at 405 nm with a 
reference of 690 nm in an ELISA reader. Confirmation of the specificity of the monoclonal 
antibody binding was achieved by digesting DNA of untreated HepG2 cells with S1 
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nuclease (10 U/μl, 30 min, 37°C) in a single stranded conformation. For an internal assay 
positive control, wells were coated with 100 μl of solution containing 0.3 μg/ml of ssDNA. 
The assay was carried out three times in triplicate.
4.4 Measurement of the cell cycle distribution of HepG2 cells
DNA content analysis also provides information about the cell cycle phase of the non-
apoptotic cells and can be applied to investigate the cell cycle specificity of apoptosis 
(Darzynkiewicz et al., 1997). The software Modifit© LT was likewise used here to 
deconvolute the DNA frequency histograms to estimate the proportions of cells in 
particular phases of the cell cycle. The cells were treated and prepared for analysis as 
described in chapter 4.3.3. An example of the software supported cell cycle analysis is 
given in figure 4. 
Figure 4: Cell cycle analysis of HepG2 cells. a) DMSO-treated and b) 20 μM MTBITC-treated cells 
analysed for their DNA content distribution after 24 h. The analysis was conducted with the software 
Modifit. A clear accumulation of cells at the G2/M phase can be seen after treatment with 20 μM MTBITC 
for 24 h.
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S
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4.5 Detection of DNA damage by the Comet assay
The single cell gel electrophoresis assay (SCGE; Comet assay) detects DNA damage and 
DNA repair on the single cell level by electrophoretic separation of DNA fragments (Singh 
et al., 1990; Tice et al., 1990). The cells are lysed and separated by an electrophoretic field. 
After electrophoresis and staining of the DNA with ethidium bromide, the migrated DNA 
resembles a comet tail, the non-migrated DNA the head, hence the naming. Depending on
the experimental conditions, i.e. the pH, the comet assay detects single or double strand 
breaks as well as alkali labile sites and DNA crosslinks. 
Figure 5: DNA migration of HepG2 cell in the Comet assay. 1) HepG2 cells after treatment with 0.1 %
DMSO. The cells are round no DNA migration is visible after alkaline lysis, electrophoresis and fluorescence 
staining with ethidium bromide (magnification 400 x)
2 to 4) HepG2 cells after treatment with B(a)P in a concentration range of 25 μM, 50 μM or 100 μM for 24 h. 
Images were made after alkaline lysis, electrophoresis and fluorescence staining with ethidium bromide 
(magnification 400 x)
So far, a large number of DNA damaging agents have been evaluated with the comet assay 
(see for reference Fairbairn et al., 1995; Faust et al., 2004; Knasmuller et al., 2004; 
Mersch-Sundermann et al., 2004; Rojas et al., 1999; Tice and Strauss, 1995). The comet 
assay is highly sensitive and enables the detection of only a few hundred breaks per cell 
(Collins et al., 1997).
Fully frosted slides were cleaned with ethanol/aceton-solution (v/v 1: 1). Next, they, were 
covered with two layers of normal melting point (NMP) agarose (1st layer 1 %, 2nd layer 
0.7) and solidified at 4°C for 15 min. 3 x 105 cells were seeded in a 12- well plate and 
exposed to the test substance at exponential growth for 1 h. After harvesting, the cells were 
2 3 4
1
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mixed with 100 μl of 0.5 % low melting point (LMP) agarose and layered on top of the 
slide. After solidification at 4°C, the cells were lysed at pH 10 for 1 h at 4°C, treated with 
unwinding buffer for 20 min and subsequently electrophoresed at pH 13 for 25 min at 300 
mA, 25 V. After electrophoresis, the cells were incubated in neutralization buffer (pH 7.5) 
for 10 min and washed with distilled water. Directly before analysis, the cells were stained 
with 10 μg/ml ethidium bromide. Analysis was performed with a CCD camera, connected 
to a fluorescent microscope (excitation wavelength 254 nm) and an image analysis system 
(Optilas inc.); densitometric evaluation was carried out with the software Comet 5.5 
(Optilas, Germany). The parameter olive tail moment (OTM) was used for the description 
of the results. It was calculated as follows:
ŇPKmSŇx DNATail, wheras ŇmKmSŇ = Distance between mass-center of comet head to 
mass-center of comet tail.
4.6 Analysis of the mitochondrial membrane potential (MMP)
Disruption of the MMP precedes the gross morphological changes associated with 
apoptosis. It is reported that this effect comes before activation of the caspase cascade and 
phosphatidylserine transposition. But it presents a point just beyond final commitment. The 
MMP is generated by production of energy using the mitochondrial respiratory chain. This 
energy drives ATP synthesis and is stored as an electrochemical gradient consisting of a 
transmembrane electrical potential, negative inside of about 180-200 mV, and a proton 
gradient of about 1 unit. Loss of the MMP, which presents one part in the permeability 
transition process, involves redistribution of ions resulting in the loss of the net negative 
charge of the matrix. 
For detection of changes in the MMP at the single cell level, the lipophilic cation 5,5',6,6'-
tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1) was used. This 
probe enters selectively into mitochondria and is capable of changing reversibly the colour 
from green to orange, depending on the polarization of the mitochondrial membrane (over 
values of about 80-100 mV). Consequently, a decrease in the red/green fluorescence 
intensity ratio indicates mitochondrial depolarization. 
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After exposure to MTBITC, the cells were harvested by trypsination, washed twice with 
PBS and resuspended in 1 ml of culture medium prewarmed to 37°C supplemented with 
the probe JC-1 at a final concentration of 2.5 μg/ml. The pH of the samples was carefully 
checked to be at 7.4 since the formation of J-aggregates is very sensitive to this parameter. 
The samples were gently vortexed and incubated under cell culture conditions for 30 min. 
Afterwards, the cells were again washed two times with ice cold PBS. Then they were 
finally resuspended in 500 μl PBS and directly analysed by a FACSCalibur in FL-1 and 
FL-2 (BD, USA). A concentration of 10 μM valinomycin was used as positive control. 
4.7 Detection of reactive oxygen species by DHR123
Altered activity of free-radical process in cell systems is associated with cell signalling and 
apoptosis induction. As shown in earlier studies, reactive oxygen species, including 
hydrogen peroxide (in the presence of peroxidase or cytochrome c) and peroxynitrite can 
be detected by dihydrorhodamine 123 (DHR123) (Henderson and Chappell, 1993; Kooy et 
al., 1994). DHR123 enters readily into most of the cells and is oxidized to the fluorescent 
product form rhodamine 123, a positively charged lipophilic compound, which is 
sequestered intracellularly (Johnson et al., 1980). Rhodamine 123 will preferentially 
accumulate within mitochondria to a marked degree with little loss to the extracellular 
space. It has been reported that DHR 123 establishes stable intracellular concentrations 
within 15 min and intracellular levels remain stable for at least 1 h as long as there is 
continued presence of probe in the extracellular medium (Royall and Ischiropoulos, 1993).
Figure 6: Analysis of the mitochondrial membrane potential. Scatter blot of a) polarized mitochondria 
(high FL1, high FL2) after treatment of HepG2 cells with 0.1 % DMSO and b) valinomycin-induced 
depolarization of mitochondria (higher FL1, lower FL2) in HepG2 cells, as revealed by staining with JC-1. 
The red/green fluorescent ratio decreases if the MMP drops. 
a) b)
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DHR123 was dissolved in DMSO at a concentration of 5 mM. The stock solution was 
purged, covered with a layer of N2 and stored at –20°C in the dark until use. For the 
experiments, DHR123 was diluted in culture medium w/o phenol red to a final 
concentration of 5 μM. Before test substance-exposure, HepG2 cells were incubated with a 
final concentration of 5 μM DHR123 in culture medium w/o phenol red for 15 min in the 
dark and afterwards exposed to MTBITC. Fluorescent intensity due to the conversion of 
DHR123 to the fluorescent DHR was measured with an ELISA reader (Infinite M200, 
Tecan, Austria) at an excitation wavelength of 500 nm and an emission wavelength of 536 
nm. HepG2 cells incubated with 5 μM DHR123 were used as background control to detect 
spontaneous oxidation of DHR123 to rhodamine 123. For correction of autofluorescence, 
every measurement was paralleled by a set of the same samples lacking DHR123 
incubation. The assay was carried out three times in triplicate.
Figure 7: Production of reactive oxygen species (ROS) determined by the conversion of DHR123 to the 
fluorescent RH123. For experimental setup, HepG2 cells were incubated with DHR123 at different 
concentrations of 5 μM, 10 μM or 50 μM for 15 min and subsequently exposed to H2O2 in a concentration 
range of 10 to 300 μM for 1 hour. To determine the optimal concentration of DHR123, 5 to 50 μM of the 
reagent were added to the treated cells which were then analysed for the production of ROS. Fluorescence of 
hydrogen peroxide-treated HepG2 cells was measured with an ELISA reader (Ex: 500 nm, Em: 536 nm), SC 
= distilled water  (N = 2).
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4.8 Determination of the glutathione status
7KH WULSHSWLGH Ȗ-glutamylcysteinylglycine or glutathione (GSH) is widely distributed in 
cells and has been shown to participate in a multitude of cellular functions. GSH serves as 
a nucleophilic co-substrate to glutathione transferases in the detoxification of xenobiotics 
and many of these functions are associated with protection against reactive intermediates, 
including free radicals and electrophiles. The maintenance of a suitable thiol-redox-balance 
with low-molecular weight and protein thiols is also crucial for cellular homeostasis. 
Glutathione content of HepG2 cells was measured with a kit from Cayman, Germany. The 
assay is based on the reaction of the sulfhydryl group of GSH with 5.5´-dithiobis-2-
nitrobenzoic acid (DTNB) to the yellow coloured 5-thio-2-nitrobenzoic acid (TNB). The 
rate of the TNB produced is thus directly proportional to the concentration of GSH in the 
samples. Since the oxidized form GSSG is easily reduced to GSH by the provided GSH 
reductase, the total glutathione content of the cells is measured. The samples were 
harvested by scraping with a rubber policeman and washed twice with PBS. After 
centrifugation (700 g, 5 min, 4°C) the supernatant was decanted and the cells resuspended 
in 300 μl PBS and subsequently lysed on ice by sonication (set to impulse, 50 sec). The 
lysate was centrifuged (10.000 g, 20 min. 4°C) and 250 μl of the GSH containing 
supernatant deproteinated with 10 % MPA reagent in a new eppendorf cup. Therefore, the 
sample was mixed with MPA 1:1, vortexed and incubated at RT for 5 min before 
centrifugation (5000 g, 5 min, 4°C). The supernatant was transferred to a new eppendorf 
cup and stored at –20°C until assaying. For assaying, all reagents were pre-warmed to RT 
before use. In order to increase the pH of the samples, 5 μl of TEAM reagent were added 
to 100 μl of sample and immediately vortexed. The provided GSSG standard was diluted 
as described in the manual to cover a concentration range of 0 to 8 μM GSH. 50 μl of the 
standards or the samples were transferred into a 96well plate and 150 μl of freshly 
prepared assay cocktail consisting of 102 μl MES buffer, 4 μl cofactor mix, 19 μl enzyme 
mix, 20.9 μl aqua dest. and 4 μl DTNB added to each sample. The plate was shaken in the 
ELISA reader for 30 sec and measured at 5 min intervals for 30 min at an absorbance of 
A410-690 nm. The results were calculated by comparison with the generated standard curve. A 
representative GSH standard curve is given in figure 8. The assay was carried out two 
times in triplicate.
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Figure 8: GSH standard curve covering a range of 0 to 8 μM. 
4.9 Telomerase activity measurement by TRAP-ELISA
Telomerase activity was detected by a photometric enzyme immunoassay, commercially 
available from Roche. This assay utilizes the polymerase chain reaction (PCR)-based 
telomeric repeat amplification protocol (TRAP) and ELISA assay for semi-quantitative 
determination of telomerase activity (Wright et al., 1995). In the first step, telomerase adds 
telomeric repeates to the 3´end of a biotinylated telomerase substrate oligonucleotide. After 
terminating the telomerase activity, the extended products are amplified by PCR reaction 
using Taq polymerase. This extension generates a ladder of products with 6 base 
increments detectable with a 12 % PA-gel and staining with SYBRgold. During the ELISA 
assay, the labelled products are immobilized onto a streptavidin-coated microtiter plate via 
biotin-streptavidin-interaction and detected by an antibody conjugated to HRP. The 
amounts of TRAP products is determined by means of the HRP activity using the substrate 
3,3`,5,5`-tetramethylbenzidine (TMB) and subsequent colour development. The assay was 
carried out according to the manufacturers´ instructions with slight modifications. The 
samples were harvested with a rubber policeman and lysed with 200 μl of the provided 
lysing buffer for 15 min on ice before centrifugation (16.000 g, 30 min., 4°C). 
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Figure 9: Titration of HepG2 protein concentration (0.001 to 10 μg) for telomerase detection by the 
TRAP assay, a) qualitative detection after gel electrophoretic separation of the PCR products by an 12 % AA 
gel and SYBRgold staining b) detection of telomerase activity by ELISA reaction at an absorbance of A405 -
690 nm.
175 μl of the supernatant were transferred to a new eppendorf cup, shock frozen in liquid 
nitrogen and stored at –80 °C until use. 0.05 μg of sample were set to a volume of 25 μl 
with DEPC-treated distilled water and mixed with 25 μl of the provided reaction mixture 
containing the biotinylated telomerase substrate P1-TS, the optimized anchor-primer P2, 
nucleotides and Taq DNA polymerase. For background correction, an aliquot of each 
sample, containing the same amount of protein was treated with 0.1 μg/μl RNase (DNase 
free) and incubated at 37°C for 20 min. An equal volume of lysis solution served as 
reagent control. PCR settings were as follows:
Step Time [s] T [°C] No of cycles
Primer elongation 1800 25
Telomerase inactivation 300 94
Amplification
Denaturing 30 94
Annealing 30 50 30
Synthesizing 90 72
600 72
Storage 4
For the qualitative analysis of telomerase activity, 30 μl of the PCR product were mixed 
with loading buffer and loaded onto a 12 % acrylamide gel in 1 x TBE buffer. The current 
0
0,2
0,4
0,6
0,8
1
1,2
1,4
0,001 0,01 0,1 1 10
HepG2 protein concentration [μg/μl]
A
bs
or
ba
nc
e 
[4
50
/6
90
 n
m
]
a) b)
IV. Methods                                                                                                          34
was set to 50 V for 30 min and then to 190 V for 3 h. After electrophoresis, the gel was 
stained with SYBRgold solution in 1 x TBE for 20 min and then detected under UV-light. 
10 μg of a 50 bp DNA size marker were run in each gel. For ELISA detection, 2.5 μl of the 
amplification product were mixed with 10 μl of denaturation reagent and incubated at RT 
for 10 min. Then, 100 μl of hybridization solution was added and incubated for 2 h at 37°C 
at 300 rpm on a minishaker. The supernatant was removed, the wells were washed three 
times with 250 μl of washing buffer for 30 sec. each and 100 μl anti-DIG-HRP working 
solution was added to each sample for 30 min at RT while shaking. The solution was 
removed and the wells were washed 5 times with 250 μl of washing buffer for 30 sec. each 
before addition of 100 μl of TMB substrate to each well for colour development. The 
reaction was stopped after 2 min by 100 μl of stop reagent producing a change in colour 
from blue to yellow. The absorbance of the samples was detected at A450-690nm with an 
ELISA reader (Infinite M200, Tecan).
The TRAP-ELISA assay was optimized by titration of the protein concentration in the 
range of 0.001 μg to 10 μg to determine the linear range of the PCR reaction and to 
minimize the influence of PCR inhibitors. Figure 10 displays the results of the titration 
experiments. A concentration of 0.05 μg protein was used for all further experiments. 
Experimental setup was then carried out by the treatment of HepG2 cells with TMPyP4 in 
a concentration range of 30 to 300 μM for 24 h and processed as described in this chapter. 
The results of the experimental setup are summarized in figure 10.
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Figure 10: Experimental setup of telomerease measurement with TMPyP4. Suppression of telomerase 
activity by TMPyP4 was detected after 24 h-treatment of HepG2 cells in the TRAP assay. The cells were 
exposed to TMPyPy in a concentration of 100 to 300 μM and subsequently prepared as described above. a) 
qualitative detection after gel electrophoretic separation of the PCR products by an 12 % AA gel and 
SYBRgold staining  b) detection of telomerase activity by ELISA reaction at an absorbance of A405 -690 nm.
The experiments were performed three times. SC: solvent control = 0.1 % DMSO.
4.10 Telomere length assessment by flow-FISH
Telomere length was determined by flow-FISH methodology using the Telomere PNA 
kit/FITC from Dako, Denmark (Cat no. K5327). The assay is based on labeling telomeres 
by introduction of synthetic, fluorochrome-tagged peptide nucleic acid (PNA) probes that 
mimic the DNA sequences complimentary to the telomere sequence ((CCCTAA)3). These 
PNA probes have been shown to be very reliable for FISH analysis of telomere length 
(Baerlocher et al., 2002; Lauzon et al., 2000; Law and Lau, 2001). Rufer et al. (Rufer et al., 
1998) have established an empirically determined association between the approximate 
number of telomere repeats, PNA probe binding and fluorescence. However, for each flow 
cytometer, a calibration for the number of non-covalently bound PNA probes per telomere 
repeat has to be carried out to be linked directly to internal fluorescence value (Kapoor and 
Telford, 2004).
At the beginning and end of each measurement, the FACS system was calibrated and 
checked for linearity using molecules of equivalent soluble fluorochrome (MESF) 
b)a)
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QuantumTM FITC beads (low) (Polyscience, Germany) to accurately quantify telomere 
length (i. e. number of telomere repeats) by correlating a specific fluorescence intensity 
value with an actual number of fluorochrome molecules which in consequence correlates 
with the number of PNA probes bound. Statistical analysis was carried out by the setting of 
markers, defining the „mean fluorescent intensity“(MFI) compared to the total event 
number with the software Cellquest pro (see figure 11). The MFI is a measure for the 
amount of bound fluorescence dye per particle. As an internal control the human T-cell 
CCRF-CEM leukaemia line was used (DSMZ, Germany), known for their long telomeres 
(Foley et al., 1965). This cell line was established from the peripheral blood of a 3-year old 
Caucasian girl with acute lymphoblasic leukaemia at relapse in 1964. The cells were grown 
in RPMI medium supplemented with 2 mM L-glutamine and 10 % FCS in a 5 % CO2-
atmosphere with 95 % humidity at 37°C. 
Figure 11:  a) Analysis of the MESF beads in the FL1 channel and defining the mean fluorescence intensitiy 
(MFI) values for the background (red coloured peak) and the FITC-stained particles (blue coloured peaks) b) 
conversion of MFI to MESF values and generation of the calibration curve
The samples were harvested by trypsination and washed twice with PBS, containing 0.1 % 
FBS. A sample containing 1 x 106 HepG2 was incubated with 300 μl hybridization 
solution with telomere PNA probe at a final concentration of 0.3 μg/ml. For correction of 
auto-fluorescence, an aliquot of the same sample was incubated with hybridisation solution 
containing no probe. The samples were denatured at 82°C for 10 min and subsequently 
hybridized for 12 h in the dark at RT. The cells were then washed twice by adding 1 ml of 
the provided washing solution and incubation for 10 min at 40 °C. After the washing step, 
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the DNA was stained with 0.5 ml staining solution for 3 h at 4°C and the samples 
subsequently analyzed in a FACSCalibur (BD, USA). 2 x 106 CCRF-CEM cells were 
processed as described above and used as internal control. For selection of the single cell 
population the cells were analyzed in FL3-A and FL3-W. The selected cells were then 
displayed in FSC vs. FL3-H dot plot. For calculation of the relative telomere length (RTL) 
per genome equivalent, cells in the G0/1-phase of the cell cycle were identified (see figure 
12). All fluorescence compensation was set to zero and the FITC detector was left at the 
same voltage as that used for the MESF beads. 
Figure 12:  a) Scatter gating of the G0/1-phase (R1) in the analysis of the cell cycle distribution of HepG2 
cells after PI staining. The forward-angle light scatter (FSC) is plotted against FL3 b) verification of the gated 
G0/1-phase cells (blue coloured peak) in a DNA histogram. Only G0/1-phase cells were used for further 
telomere length analysis. 
The RTL value was calculated in relation to the telomere length of CCRF-CEM control 
cells by the following equation: 
RTL (%) = (mean MESF sample cells with probe – mean MESF sample cells w/o probe)  x 100
 (mean MESF control cells with probe – mean MESF control cells w/o probe) 
a) b)
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4.11 Protein analysis by immunoblotting
Proteins were analysed by immunoblotting, also referred to as western blotting after a 
modified protocol by Burnette (Burnette, 1981). This methodology uses sodium dodecyl 
sulfate polyacrylamide gel electrophoresis  (SDS-PAGE) to separate native proteins by 
their molecular weight. Sampled proteins become covered in the negatively charged SDS 
and move to the positively charged electrode through the acrylamide mesh of the gel. 
Smaller proteins migrate faster through this mesh and the proteins are thus separated 
according to size. The so separated proteins are then transferred out of the gel onto a 
nitrocellulose membrane where they are probed using antibodies specific to the protein. 
Treated samples were harvested with a rubber policeman and washed twice with cold PBS. 
After final washing, the cells were chemically lysed with 200 μl of Cellytic M for 30 min 
on ice, the cellular debris separated from the proteins by centrifugation (16.000 g, 30 min. 
4°C) and 175 μl of the supernatant, containing the proteins, transferred to a new eppendorf 
cup. The aliquoted samples were shock frozen in liquid nitrogen and stored at –80°C until 
use. Protein concentration was determined after the modified method of Bradford 
(Bradford, 1976) as described in chapter 4.12.  For immunoblotting, the samples were 
thawed on ice and 20 μg of protein mixed with ready made SDS-containing sample buffer, 
supplemented with DTT at a final concentration of 0.12 mM. Electrophoresis was 
performed according to the method of Laemmli (Laemmli, 1970). The samples were 
heated to 60 °C for 5 min and then cooled on ice for 5 min before loading onto a 10 % or 
15 % discontinuous PA-gel dimensioned 9 x 6 cm. The current was first set to 1 V/cm for 
30 min and then to 2 V/cm for 60 min. The gel was then transferred to a nitrocellulose 
membrane by semi-dry or wet blotting (0.7 mA/cm2, 90 min.) and blocked with 5 % BSA 
Figure 13: FITC histogram of G0/1-phase HepG2 cells
hybridized to the telomere specific PNA probe (blue 
coloured peak) and the autofluorescence signal of PNA 
probe-negative HepG2 cells (red coloured line) 
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or milk powder in TBS/T for 24 h. After blocking, the membrane was incubated with 2 ml 
of primary antibody diluted in TBS/T containing 5% BSA for 1 to 24 h at 4°C, then 
washed three times with cold TBS/T for 5 min and subsequently incubated with a 
horseradish peroxidase (HRP)-labeled secondary antibody for 1 to 24 h. After antibody 
incubation, the membrane was washed again three times with cold TBS/T and detected 
with a chemiluminescent agent (2 ml of solution A, 0.6 μl hydrogen peroxide (30%) and 
200 μl of solution B) producing luminescence in proportion to the amount of protein. 
Figure14: Densitometric analysis of western blots. The chemiluminescent signal of the antibody-treated 
proteins (a) was captured by a CCD camera and quantified with a software from Intas, Germany (b). The 
relative staining-amount of the protein of interest (Band 1) was then normalized to b-actin (Band 2).
A digital image of the western blot was captured by a CCD camera and the image analysed 
by densitometry, evaluating the relative amounts of protein staining and quantifying the 
result in terms of optical density normalized to b-actin with software from Intas 
(Germany). 
Size approximations were taken by comparing the stained bands to that of a protein 
standard loaded during electrophoresis. The process was repeated for the structural protein 
b-actin which should not change between samples. The amount of target protein could then 
be indexed to the structural protein to control between groups. This ensured correction for 
the amount of total protein on the membrane in case of errors or incomplete transfers.              
Immunoblotting was used to determine the protein expression levels of the tumor supressor 
gene products p53 and p63, of the murine double minute MDM2, p21WAF1and BclXL.
Furthermore the expression levels of the heat shock proteins HSP70 and HSP90 and of the 
a)
b)
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human telomerase reverse transcriptase hTERT were determined by this method. The 
specifications and dilution factors of the antibodies are given in chapter 3.5.
4.12 Determination of the protein concentration after Bradford
The protein concentration of the samples was determined by the method after Bradford et 
al. (1976) with modifications for microtiter application. This method is based on the shift 
in absorbance of Coomassie Brilliant Blue G-250 when bound to protein residues like 
arginine, tryptophan, tyrosine, histidine and phenylalanine, whereas the assay responds 8 
times more to arginine residues. Coomassie Brilliant Blue G-250 binds to these residues in 
the anionic form, which has an absorbance maximum at 595 nm (blue).  The free dye in 
solution is in the cationic form, which has an absorbance maximum at 470 nm (red). The 
extinction coefficient for the dye-protein complex is stable over 10 orders of magnitude 
(assessed in albumin). The dye reagent is stable for approximately one hour. Since the 
absorption spectra of the two forms overlap, the assay responds non-linearly in the 
standard curve over a wide concentration range. Therefore, the assay was modified after 
the method of Zor and Selinger (Zor and Selinger, 1996), who proposed the measurement 
of absorbance ratio 590/470 nm to determine the protein concentration. Bovine serum 
albumine (BSA) in a concentration range of 1 to 80 μg/ml was used to establish a standard 
curve. 
Figure 15:  Measurement of protein concentration with a modified version of the Bradford assay. A 
calibration function generated in the Bradford assay with BSA in a concentration range between 0-80 μg/ml 
after a) measurement of the absorbance at 595 nm and b) calculation of the ratio A595 /A470 nm.  
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4.13 Chemical analysis by GC-MS/MS
The reactivity and volatility of ITCs is well known (Patai, 1977). The highly electrophilic 
central carbon atom of the N=C=S group reacts rapidly, and under mild conditions with 
oxygen-, sulfur-, or nitrogen centered nucleophiles to give rise to carbamates, 
thiocarbamates, or thiourea derivatives, respectively (Zhang and Talalay, 1994). To 
investigate the stability and kinetics of MTBITC under the conditions of the cell culture 
studies, and to learn more about the origin of the ITC-decomposition, a set of experiments 
was carried out and the ITC subsequently analysed by gas-chromatography.mass 
spectrometry (GC-MS/MS). 
a) 
Figure 16: a) GC-MS/MS chromatochram of MTBITC. The retention time of MTBITC under the applied 
conditions was 8.859 minutes, b) calibration curve for the GC-MS/MS measurements of MTBITC. The 
calibration was performed in a concentration range of 0-100 μM MTBITC. MTBITC was therefore diluted in 
cyclohexane/ethylacetate (v/v).  
T25 cell culture flasks containing
A. 1 x 106 adherent growing HepG2 cells in 5 ml culture medium and MTBITC at a 
final concentration of 20 μM were covered with a 0.22 μM-filter cap.
B. only 5 ml culture medium and MTBITC at a final concentration of 20 μM were
covered with a 0.22 μM-filter cap.
C. 5 ml of distilled water and MTBITC at a final concentration of 20 μM were 
covered with a 0.22 μM-filter cap.
D. 5 ml of distilled water and MTBITC at a final concentration of 20 μM were sealed 
air- and liquid-tight with a sealing film (Nescofilm).
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The flasks were then incubated at 37°C, in a 5 % CO2- atmosphere and 95 % humidity for 
0-24 h. After incubation, 2 ml of the liquid were removed from the flask and mixed 
vigorously with 1 ml of cyclohexane/ethylacetate (1:1) for 2 x 1 min. For phase separation, 
the suspension was centrifuged (5000 g, 10 min, 4°C) and the organic phase containing 
MTBITC transferred to a 15 ml falcon. The procedure was repeated and the second layer 
of organic phase added to the first one. 
Chemical analysis and quantification of MTBITC was performed by a GC-MS/MS from 
Varian, Germany. The flow rate of the helium carrier gas was set to 1 ml/min. The 
temperature settings are shown in table 12.
Table 12: Temperature program of the varian GC capillary column, injector and transferline
Appliance T [°C] T increase [°C/min] T hold [min]
capillary column 30 0.5
90 5.0 5.0
160 5.0 5.0
280 30 10.0
Injector (injection volume = 1 μl) 210
MS/MS transferline 210
Mass spectra were obtained by electron ionisation at 70 eV, in single ion mode (SIM) at 
the mass 115 after 8.595 min. Quantification was performed with an external standard 
calibration function for each compound.
For quality control, the recovery rate of 10 to 100 μM MTBITC in the culture medium was 
determined in triplicate.
4.14 Statistical data analysis 
Statistical analysis of the experimental data was performed with the software SPSS 11.0 
for Windows. The samples were described by the mean value or median ± standard 
deviation (SD).  All results were derived from at least two independent experiments. The 
data were analysed for significance of difference compared to control by the Students´ t-
test.
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V. RESULTS
5.1 MTBITC inhibits the proliferation of HepG2 cells
At the beginning of the study, a first characterization of MTBITC was achieved by 
detection of progress in cell proliferation after chemical- treatment with the WST-1 test, 
which measures the activity of mitochondrial succinate dehydrogenases of living cells. 
These experiments were conducted over a three-day time period in a concentration range 
of 1 to 30 μM MTBITC. 
Figure 17: Spectrophotometric quantification 
of cell growth after MTBITC exposure. The 
number of viable cells after MTBITC-treatment 
was determined by the cleavage of WST-1 to 
formazan, displayed as change in absorbance at 
A450-620 nm at the indicated time points. (N = 3) C: 
control = untreated cells; SC: solvent control = 
DMSO 0.1 %, * P    3  
statistically significant compared to solvent 
control. 
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Figure 17 summarizes the results of three independent experiments. A concentration and 
time-dependent reduction in proliferation activity could be observed in cells treated with 
MTBITC exceeding 10 μM. After 24 h exposure of HepG2 cells to MTBITC in a 
concentration of 20 μM, a significant change in the proliferation activity of the cells 
compared to control cells could be observed. At this concentration, a proliferation 
reduction of HepG2 cells by 35 % was detectable (0.64 ± 0.05 vs. 0.42 ±0.61). This 
difference in proliferation activity compared to the control cells persisted after 48 h (1.22 ± 
0.31 vs. 0.63 ± 0.92) and even after 72 h around 60 % of cells were still WST-1 positive 
(1.77 ± 0.15 vs. 1.07 ± 0.29). The treatment with MTBITC in a concentration range 
between 1 to 10 μM MTBITC for up to 72 h had no inhibitory effect on HepG2 cells, but a 
slight increase after 72 h could be detected in comparison to control cells (2.25 ± 0.44 vs. 
1.77 ± 0.15). Exposure of cells towards 30 μM MTBITC for 24 h to 72 h resulted in a 
successive growth inhibition of  45 %, 70 % and 85 %, respectively.
Additionally to the WST-1 test, the protein content of HepG2 cells was determined as an 
indication for proliferation. The results are depicted in figure 18. The protein content of 
HepG2 cells exposed to 20 μM MTBITC was already reduced after 24 h to 76 % of control 
(3.23 ± 0.31 vs. 4.20 ± 0.56).  After 48 and 72 h, the concentration was further reduced to 
33 and 6 % of control (1.40 ± 0.15 and 0.28 ± 0.09, respectively).
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Figure 18: Quantification of the protein content 
of MTBITC-treated HepG2 cells by a modified 
version of Bradford. 2 x 106 cells were seeded into 
T25 culture flasks and exposed to 20 μM MTBITC 
at exponential growth. The protein concentration of 
lysates was determined after the indicated time 
points. (N = 4) SC: solvent control = lysate of 
HepG2 cells treated with 0.1 % DMSO for 72 h. * P 
   3   VWDWLVWLFDOO\ VLJQLILFDQW
compared to solvent control
**
**
V. Results                                                                                                                              45
5.2 Apoptosis is induced in a concentration- and time-dependent manner
The inhibitory effect of MTBITC on the proliferation of HepG2 cells was further 
characterized to determine whether the observed reduction in viability was of necrotic or 
apoptotic origin. Therefore, internucleosomal DNA fragmentation, representing one of the 
hallmarks of apoptosis was measured by two methodologies, the analysis of discrete 
“subG1” peaks on a DNA histogram by flow cytometry and the separation of fragmented 
DNA on an agarose gel. The results of these experiments are displayed in figures 19 and 
20, respectively.
After 24-h exposure of HepG2 cells with MTBITC, DNA content analysis revealed a 
concentration-dependent increase in the formation of hypoploid DNA, which peaked at a 
concentration of 20 μM. At this concentration, the measurement of the “subG1” DNA 
content resulted in a 16.03 ± 1.52 % increase. Compared to that, exposure of the cells to 
the solvent control DMSO and to the positive control CPT led to an increase of 2.21 ± 0.25 
% and 15.8 ± 2.65 % hypoploid events, respectively. A further increase in the 
concentration of MTBITC resulted in a reduction of the “subG1” DNA content, probably 
due to the accumulation of necrotic events. 
Positive 
The process of apoptosis induction after MTBITC treatment of HepG2 cells over time was 
tracked with the detection of the DNA fragmentation in the DNA laddering assay. 1 or 3 h 
post-treatment, no apoptotic DNA was present. However, after 6 h-incubation with 20 μM 
MTBITC distinct apoptotic changes could be observed. The amount of fragmented 
apoptotic DNA increased even further after 24 h-detection. No DNA fragmentation could 
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Figure 19: 
Alteration in the “subG1” DNA content of 
HepG2 cells after exposure to MTBITC in a 
concentration range between 1 to 30 μM for 24 
h.  (N = 3) SC: solvent control = 0.1 % DMSO, 
+: positive control = 6 μM CPT. * P  
statistically significant compared to solvent 
control
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be seen with untreated or 0.1 % DMSO treated cells. No signs of necrotic events, visible as 
a smear in the agarose gel, were detected after exposure of HepG2 cells with 20 μM 
MTBITC for the indicated time-points. 
Figure 20: 
Induction of internucleosomal DNA fragmentation 
after treatment of HepG2 cells for 1 to 24 h. The 
apoptotic DNA was separated by a 2 % agarose gel in 
an electric field and stained with ethidium bromide. M: 
100 bp DNA size marker; C: untreated HepG2 cells; 
SC: solvent control = 0.1 % DMSO; +: positive control 
= 5.7 μM CPT. The experiments were carried out three 
times.
It is known that early during apoptosis only a small fraction of DNA is degraded to the size 
of internucleosomal fragments, while in more advanced stages nearly all the DNA is 
fragmented. Thus, the amount of low MW DNA varies manifold depending on the stage of 
apoptosis. As a consequence, the total content of low MW DNA does not provide 
information about the frequency of apoptotic cells. The “sub-G1” peak can represent, in 
addition to apoptotic cells, mechanically damaged cells or cellular debris. Moreover, cells 
in a late necrotic stage are also characterized by a loss of DNA and may therefore be 
stained similarly to apoptotic cells on a DNA histogram. To ascertain the present results 
and to quantify the amount of MTBITC-induced apoptotic cells, in addition, specific 
detection of single stranded apoptotic DNA with a monoclonal antibody was conducted. 
These results are shown in figure 21.
  M    C   SC     1     3     6    24    +
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In accordance to the DNA fragmentation analysis, no apoptosis could be detected after 1 or 
3 h-exposure of HepG2 cells to 20 μM MTBITC with the ssDNA assay. A time-dependent 
increase could be observed beginning after 6 h-treatment of cells with MTBITC. After that 
time, a 1.6-fold increase in absorbance at 405 nm was detected, due to the staining of 
single stranded apoptotic DNA compared with the control (0.44 ± 0.69 vs. 0.3 ± 0.03) . 24 
h after the addition of 20 μM MTBITC to HepG2 cells, 46 % of the DNA of treated cells 
were stained with the Mab compared to control. Interestingly, 1 and 3 h after treatment 
begin, the apoptotic signal was slightly suppressed compared to the control. 
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Figure 21: Formation of formamide denatured, 
single stranded apoptotic DNA in HepG2 cells. 
The cells were treated with MTBITC in a 
concentration of 20 μM for the indicated time 
points and apoptotic DNA stained with a Mab 
specific for ssDNA. (N = 3) SC: solvent control = 
0.1 % DMSO; +: positive control = 6 μM CPT; IC: 
intern positive control = single stranded DNA. S1 
Nuclease denatured HepG2 cells were used to 
confirm the specificity of the MAb binding. 
Absorbance of these cells was   LQ DOO WKUHH
experiments. * P   DQG  3  
statistically significant compared to solvent control
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5.3 The cell cycle progression is halted by MTBITC
Besides apoptosis induction, the decrease in cell proliferation detected with the WST1 
assay after MTBITC-treatment could be a consequence of a cell cycle arresting influence 
of the ITC on the hepatoma cell line. Therefore, in the next step, the effect of MTBITC on 
cell cycle progression was analysed using flow cytometry. Results derived from three 
independent experiments are depicted in figure 22. A time-dependent arrest at the G2/M 
phase of the cell cycle was apparent at 6 h after MTBITC-treatment. At that time, 22.28 ± 
3.45 % of MTBITC-treated HepG2 cells were arrested in the G2/M phase compared to 
6.11 0.63 % of control cells. After 24 h, the amount of cells in the G2/M population 
increased from 10.31 ± 0.38 % of control cells to 59.42 ± 2.05 % of MTBITC-treated cells. 
The increase in the cell population at the G2/M phase was accompanied by a decrease in 
the cell population at the G1 phase of the cell cycle. 
Figure 22: Analysis of cell cycle distribution after treatment of HepG2 cells with 20 μM MTBITC for 1 to 
24 h by flow cytometry and PI staining of DNA. Cell cycle analysis was carried out with the software 
Modifit. (N = 3) Control: HepG2 cells, treated with 0.1 % DMSO.
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b-actin
p21WAF1
5.4 p21WAF1 is increased by MTBITC-treatment
Eucaryotic cell cycle progression is regulated by sequential activation of cyclin-dependent 
kinases (cdks). p21WAF1 is ubiquitously expressed in mammalian cells and a well 
characterized cyclin-dependent kinase inhbitor that functions as a negative modulator of 
cell cycle progression (Gartel and Radhakrishnan, 2005). It is also a major target for 
transactivation by the tumor suppressor p53 and plays a cruical role in mediating growth
arrest when cells are exposed to DNA damaging agents. To elucidate the mechanism of 
MTBITC-induced cell cycle arrest, lysates from control and MTBITC-treated HepG2 cells 
were subjected to western blotting using an antibody specific for p21WAF1. The results of 
densitometric scanning and a representative immunoblot for the effect of MTBITC on the 
expression level of p21WAF1 are shown in figure 23. The expression of p21WAF1 was 
comparable to the control after 1 h of treatment with MTBITC. After 3 h, a 10 %-increase 
in the expression of p21WAF1 could be detected compared to the control; 6 h after treatment 
begin the protein level of  p21WAF1 was elevated by 30 % compared to the control, which 
further increased to 50 % after 24 h and stabilized thereafter.  
Figure 23: Time-dependent activation of p21WAF1 after exposure of HepG2 cells towards 20 μM 
MTBITC for 1 to 48 h. Cells were processed for immunoblot analysis and antibody probed. Lysate from 
HepG2 cells exposed to 0.1 % DMSO for 48 h were included as control. Left side: results of densitomentric 
scanning of the immunoreactive bands corresponding to p21WAF1. The figure presents the mean of two 
independent immunoblot-experiments, normalized to b-actin ± SD. The results are expressed relative to the 
control, which was set to zero. Right side: representative blot of HepG2 protein lysate after p21WAF1 or b-
actin antibody incubation. 
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5.5 MTBITC directly modifies the MMP
The loss of the MMP precedes the gross morphological changes associated with apoptosis. 
However, it represents a point just beyond final commitment. To explore the possible 
mechanism by which MTBITC induced apoptosis in HepG2 cells, the effect of the ITC on 
the mitochondrial membrane potential was investigated in time course experiments by flow 
cytometric analysis with the fluorescent probe JC-1. Representative scattergrams for red 
(indicator of an intact mitochondrial membrane potential) and green (indicator of 
mitochondrial collapse) fluorescence in HepG2 cells are shown in figure 24. In DMSO-
treated control cells, mitochondria exhibited red fluorescence, due to accumulation of J-
aggregates, indicating an intact mitochondrial membrane potential (figure 24.a). MTBITC-
treatment disrupted the mitochondrial membrane potential in a concentration-dependent 
manner, as revealed by an increase in green fluorescence resulting from cytosolic 
accumulation of monomeric JC-1 (figures 24. b to d). Disruption of the MMP of HepG2 
cells by MTBITC-treatment was not evident for 6 h. As shown in figure 25, exposure for 3 
h did not alter the MMP, after 6 h however, a concentration-dependent disruption of the
MMP was initialized, which dramatically amplified after 24 h. Compared to the control, 6 
h-treatment of cells with 20 μM and 30 μM led to a reduction in the MMP of about 20 % 
and 45 %, respectively. After 24 h, the treatment of cells with 20 μM and 30 μM MTBITC 
resulted in a complete loss of the MMP. But even 3 μM MTBITC had a depolarizing effect 
on the mitochondria after 24 h.
**
**
Figure 24: 
Scattergrams of the MMP collapse 
after exposure of HepG2 cells to 
MTBITC. The pictures on the right side 
show the events detected in the FL-1 vs. 
FL-2 channel, after staining of cells with 
2.5μg/ml JC-1 for 30 min. a) control 
cells, b) HepG2 cells treated with 20 μM 
MTBITC for 6 h, c) HepG2 cells treated 
with 20 μM MTBITC for 24 h, d) 
HepG2 cells treated with the positive 
control 10 μM valinomycin for 24 h. 
a)
c)
b)
d)
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Figure 25: MMP collapse of MTBITC-treated 
HepG2 cells. Cells were exposed to MTBITC at 
3 to 30 μM for the indicated time points. For 
MMP analysis, the treated cells were incubated 
with the fluorescent probe JC-1 at a concentration 
of 2.5 μg/ml for 30 min. and analysed in a 
FACSCalibur, BD. (N = 3) SC: solvent control, 
0.1 % DMSO; +: positivel control = 10 μM 
valinomycin. The results were expressed as % of 
control cells. * P 3VWDWLVWLFDOO\
significant compared to control
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5.6 The anti-apoptotic protein BClxL is suppressed
It has been shown in a variety of cellular systems that members of the Bcl-2 family 
function as gatekeepers of the cell death process. The anti-apoptotic multi-domain Bcl-2
protein BclxL interacts and inhibits the function of pro-apoptotic Bcl-2 proteins. 
Furthermore, the disruption of the MMP is often accompanied by the suppression of anti-
apoptotic proteins of the Bcl-2 family, which were found to be predominantly localized at 
the outer mitochondrial membrane. To confirm the involvement of mitochondria in 
MTBITC-induced cell death and to gain insight into the underlying mechanism of 
apoptosis induction by MTBITC, its effects on the expression level of Bcl-xL was 
determined by immunoblotting. To ensure equal loading of proteins in all samples, b-actin 
control was used. Figure 26 shows the results of the densitometric analysis. A slight 
increase in BclxL protein expression of 15 % was observed after 1 h-treatment with 
MTBITC, which corresponds to the slight reduction in the apoptotic signal earlier observed 
in the ssDNA assay. Treatment of HepG2 cells with 20 μM MTBITC for KUHVXOWHGLQ
a time-dependent suppression of the BclxL protein. After 6 h, the level of BclxL was 
decreased to 40 % of control and stabilized thereafter at this level. 
Figure 26: Time-dependent suppression of BClXL after exposure of HepG2 cells to 20 μM MTBITC for 1 
to 48 h. Cells were processed for immunoblot analysis and antibody probed. Lysate from HepG2 cells 
exposed to 0.1 % DMSO for 48 h were included as control. Left side: results of densitomentric scanning of 
the immunoreactive bands corresponding to BClXL. The figure presents the mean of three independent 
immunoblot-experiments, normalized to b-actin ± SD. The results are expressed relative to the control. Right 
side: representative blot of HepG2 protein lysate after BClXL or b-actin antibody incubation.
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5.7 The GSH level of HepG2 cells is dichotomous modulated
Glutathione (GSH) is the major intracellular antioxidant and an important cofactor of the 
detoxifying metabolism. ITCs readily and strongly bind to GSH due to their electrophilic 
N=C=S-group, a mechanism which is made responsible for the fast accumulation of ITC 
within the cell (Zhang, 2000). It was already reported by Hall et al. (Hall, 1999) that GSH 
depletion renders cells more susceptible to oxidative stress, which in consequence may 
trigger the induction of programmed cell death. On the other hand, ITC have been shown 
to induce g-glutamylcsteine synthetase (GCS), the limiting enzyme of GSH synthesis 
(Scharf et al., 2003). Therefore, the influence of MTBITC on the GSH status of HepG2 
cells was investigated. The summarized results of two independent experiments are 
presented in figure 28, expressed as GSH concentration relative to the control.
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Not surprisingly, after 6 h-treatment of HepG2 cells in a concentration range of 1 to 10 
μM, the GSH level concentration-dependently increased. This effect was even further 
elevated after 24 h. Concentrations leading cells into programmed death, i.e. exposure to 
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Figure 27: Modulation of the GSH level of HepG2 cells after treatment with MTBITC in a concentration 
range between 1-50 μM for 6 or 24 h. GSH level was spectrophotometrically determined by a kit from 
Cayman, Germany, based on the reaction of the sulfhydryl group of GSH with 5,5´-dithiobis-2-nitrobenzoic 
acid (DTNB) to the yellow coloured 5-thio-2-nitrobenzoic acid (TNB). The results are expressed as GSH 
concentration relative to the control (N=2) ± standard deviation. Control: 0,1 % DMSO * P  3
0.01, statistically significant compared to control
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20 μM MTBITC, however resulted in a massive GSH depletion, which was already 
evident after 6 h and resulted in a total depletion of the major cellular oxidative defence 
after 24 h. After 6 h and 24 h, the GSH level was decreased to 41 ± 2.54 % and 15 ± 8.99 
%  respectively in cells exposed to 20 μM MTBITC, compared to the control. This 
dichotomous behaviour of MTBITC is in accordance with the increase in the proliferation 
rate of HepG2 cells treated with lower concentration of MTBITC for a prolonged time on 
the one hand and a loss in vitality and MMP collapse in the higher concentration on the 
other hand.
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5.8 ROS production is a late event in MTBITC-induced apoptosis
To confirm the production of oxidative stress due to the depletion of GSH, in a next step 
the production of reactive oxygen species by the exposure of MTBITC to HepG2 cells was 
investigated. This was done by measurement of the intracellular conversion of DHR123 to 
the fluorescent RH123, mediated by ROS. Short-term exposure of HepG2 human liver 
cells to 20 μM MTBITC for only 1 h significantly reduced the production of ROS 
compared to control cells. But after 3 h-treatment with the ITC, a concentration-dependent 
oxidation of DHR123 was monitored. This formation of ROS further increased after 6 h, at 
which time point 20 μM MTBITC produced a 10 %-increase of ROS compared to the 
control. 
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Figure 28: 
Production of reactive oxygen species (ROS) 
after exposure of HepG2 cells to MTBITC for a) 1 
h, b) 3 h and c) 6 h. ROS production was 
determined by the conversion of DHR123 to the 
fluorescent RH123. The results are displayed as % 
of untreated HepG2 cells. SC: solvent control = 
0.1 % DMSO. * P 3VWDWLVWLFDOO\
significant compared to DMSO-treated cells (N= 
4)
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5.9 The p53 family is involved in MTBITC-mediated growth suppression  
To determine whether the induction of cell cycle arrest and apoptosis in HepG2 cells was 
truly mediated by p53 expression, cells were treated with MTBITC in different 
concentrations from 1 to 24 h and analysed for their p53 protein expression level. Since the 
participation of p21WAF1 was already clear, this could also provide further information 
about the involvement of a p53-dependent or independent regulation of p21WAF1. As shown 
in figure 29a, exposure of HepG2 cells to MTBITC for 1 h led to a concentration-
dependent increase in the expression level of p53. Exposure of cells to 20 μM MTBITC 
led to a 220 % increase in p53 protein level compared to DMSO-treated cells. 30 μM, 
which showed rather strong cytotoxic effects in the viability studies, did over-express p53, 
but this effect was rather short-lived compared to treatment of cells with 20 μM, as shown 
in figure 29 b.  Stabilization of the p53 protein above control levels persisted for KLQ
HepG2 cells exposed to 20 μM MTBITC; a degradation of this tumor suppressor gene 
product was not detected until 24 h after treatment-begin (figure 29 c). 
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Figure 29: Concentration and time-dependent regulation of p53 in HepG2 cells after exposure to 
MTBITC for a) 1 h, b) 6 h and c) 24 h. Lysate from HepG2 cells exposed to 0.1 % DMSO for 1 to 24 h were 
included as control. Left side: results of densitomentric scanning of the immunoreactive bands corresponding 
to p53. The figures present the mean of three independent immunoblot-experiments, normalized to b-actin ± 
SD. The results are expressed relative to the control. Right side: representative blot of HepG2 protein lysate 
after p53 or b-actin antibody incubation.
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p63 shares similar transcriptional functions with p53, including its potential for inducing 
apoptosis and growth suppression, although with varying efficiency (Gressner et al., 2005).
With respect to this similarity between p53 and p63, the influence of MTBITC-treatment 
on the modulation of p63 was additionally investigated by western blotting. In control 
cells, no p63 protein could be detected with the applied methodology, as displayed in 
figure 30. A time-dependent increase of p63 protein content could be observed after 1 h-
treatment of HepG2 cells with 20 μM MTBITC. The protein level initially stabilized at 100 
% above the control for the first 6 hours. A further increase in p63 protein content to 230 
% of the control could be seen 6 h after exposure–begin, and after 24 h and 48 h was even 
further elevated to 420 % and 510 % of the control. 
Figure 30: Time-dependent stabilization of p63 after exposure of HepG2 cells with MTBITC at a 
concentration of 20 μM for 1-48 h. Lysate from HepG2 cells exposed to 0.1 % DMSO for 48 h were included 
as control. Left side: results of densitomentric scanning of the immunoreactive bands corresponding to p63. 
The figure presents the mean of three independent immunoblot-experiments, normalized to b-actin ± SD. The 
results are expressed relative to the control which was set to zero. Right side: representative blot of HepG2 
protein lysate after p63 or b-actin antibody incubation.
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5.10 Overexpression of the murine double minute (MDM2) oncogene 
In a next step, the observed degradation of p53 after 24 h-treatment with MTBITC was 
further examined by measuring the protein level of MDM2. It is known that due to its 
ubiquitin ligase properties, MDM2 renders p53 to proteosomal degradation and is therefore 
regarded as one of the most critical cellular antagonists of p53. Its role in p63 regulation, 
however, is not well-defined. As shown in figure 31, MDM2 was undetectable in control 
cells, whereas a time-dependent increase in MDM2 protein level could be detected in 
HepG2 cells exposed to 20 μM MTBITC. After 6-h treatment of HepG2 cells with 
MTBITC, a clear increase in MDM2 protein content to 170 % above the control could be 
observed, which peaked after 24 h with a 1000-fold increase compared to DMSO-treated 
HepG2 cells. These observations are perfectly in accordance to the chance in p53 protein 
expression and explain its observed time-dependent variation very well.  
Figure 31: Time-dependent activation of MDM2 after exposure of HepG2 cells to MTBITC at a 
concentration of 20 μM for 1-48 h. Lysate from HepG2 cells exposed to 0.1 % DMSO for 48 h were included 
as control. Left side: results of densitomentric scanning of the immunoreactive bands corresponding to 
MDM2. The figure presents the mean of three independent immunoblot-experiments, normalized to b-actin ± 
SD. The results are expressed relative to the control. Right side: representative blot of HepG2 protein lysate 
after MDM2 or b-actin antibody incubation.
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5.11 MTBITC induces DNA migration in the Comet assay
DNA strand breaks have been shown to be the initial signal in the DNA damaging 
signalling pathway of apoptosis induction and may act upstream of p53. In order to test 
whether DNA damage precedes MTBITC-mediated p53 stabilization and induction of the
programmed cell death, HepG2 cells were exposed for 1 h to 20 μM MTBITC and 
subsequently analysed in the alkaline version of the SCGE assay. As shown in figure 32, 
MTBITC was found to significantly increase the level of strand breaks, expressed as OTM, 
2.3-fold above the control level (2.1 ± 0.2 vs. 0.9 ± 0.1). The positive control 100 μM 
B(a)P induced an OTM of  2.6 ± 0.2. These results correspond to the early activation of the 
p53 family and make a good point in understanding the MTBITC-mediated effects of 
HepG2 cells observed so far. 
333N =
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** Figure 32: DNA damage induced by 20 μM 
MTBITC after 1 h exposure of HepG2 cells. 
Treated cells were separated in an electrophoretic 
field under alkaline conditions and the DNA stained 
with 10 μg/ml ethidium bromide. Analysis was 
carried out with the software COMET 5.0 from 
Optilas, Germany. SC: solvent control = 0.1 % 
DMSO, +: positive control = 100 μM B(a)P; OTM: 
olive tail moment; ** P   VWDWLVWLFDOO\
significant compared to control (N=3)
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5.12 Telomerase and telomerase activity are suppressed by MTBITC
Having proved the MTBITC-dependent over-expression of p53 family members in HepG2 
cells, the effect of the ITC on telomerase and telomerase activity was investigated in order 
to test the generated hypothesis. At first, the expression level of the catalytic subunit 
hTERT was determined by immunoblotting. The results of the hTERT expression level are 
summarized in figure 33. The analysis of hTERT revealed a continuous degradation of the 
protein, beginning 3 h after MTBITC-exposure of HepG2 cells. 24 h after treatment-begin, 
the protein was suppressed by 50 % compared to control cells. No further degradation of 
hTERT was evident after 48h.
Figure 33: Time-dependent suppression of hTERT after exposure of HepG2 cells to MTBITC at a 
concentration of 20 μM for 1-48 h. Lysate from HepG2 cells exposed to 0.1 % DMSO for 48 h were included 
as control. Left side: results of densitomentric scanning of the immunoreactive bands corresponding to 
hTERT. The figure presents the mean of three independent immunoblot-experiments, normalized to b-actin ± 
SD. The results are expressed relative to the control. Right side: representative blot of HepG2 protein lysate 
after hTERT or b-actin antibody incubation.
Since the telomerase-limiting protein hTERT was found to be time-dependently 
suppressed, the results were verified by analysis of the holenzyme activity in the TRAP-
ELISA assay. Therefore, HepG2 cells were again treated with a fixed concentration of 20 
μM MTBITC for the same time points, additionally extended to a 72 h-exposure 
experiment. The results are depicted as the typical telomerase ladder consisting of 6 bp 
DNA increments derived by the TRAP reaction (figure 34 a). Additionally in figure 34 b 
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are the summarized results generated by ELISA-detection of the same PCR products. No 
suppression of the enzyme activity could be seen for 24 h, which corresponds to the long 
half-life of the enzyme. 24 h after treatment-begin of HepG2 cells to 20 μM MTBITC, a 
decrease in telomerase activity by 10 % compared to control was detected, which 
subsequently was further reduced to 50 % after 72 h. The treatment of cells with the 
positive control TMPyP4 resulted in an 85 % loss of telomerase activity within the first 24 
h compared to control.
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Figure 34: Suppression of telomerase activity 
in HepG2 cells after treatment with 20 μM 
MTBITC. Cells were treated with MTBITC for 
the indicated time points. 0.05 μg protein extract 
of HepG2 cells were then used for TRAP-ELISA 
analysis. Preparations of HepG2 cells treated with 
0.1 % DMSO for 72 h were included as control. 
RNase-treated preparations of the samples were 
used to correct for background. a) 6 bp DNA 
increments derived by the TRAP reaction. Rows 
labelled (-) indicate the corresponding Rnase 
treated sample M: 100 bp DNA marker; C: 
solvent control = 0.1 % DMSO; + control: 
positive control = 300 μM TMPyP4. b) 
summarized results of three independent 
experiments generated by ELISA-detection of the 
PCR products. * P   DQG 3  
statistically significant compared to solvent 
control
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5.13 MTBITC-treatment increases the level of HSP proteins
The HSP90 chaperon complex plays a crucial role in the folding of the telomerase enzyme 
to its active state. But this complex is also important for a functional stabilization of p53 
during the suicidal death of cells. Therefore, the expression levels of HSP90 and HSP70 
were determined in immunoblotting experiments. In figures 35 and 36, the results of  
MTBITC-treatment on HSP-expression level in HepG2 cells are displayed. A time-
dependent increase in HSP90 accumulation was detected, beginning after 1h-treatment of 
cells with MTBITC. Compared to control, densitometic analysis showed a 3-fold over-
expression of HSP90 in HepG2 cells harvested after 24 h of exposure to MTBITC. 
Figure 35: Time-dependent over-expression of HSP90 after exposure of HepG2 cells with MTBITC at a 
concentration of 20 μM for 1-48 h. Lysate from HepG2 cells exposed to 0.1 % DMSO for 48 h were included 
as control. Left side: results of densitomentric scanning of the immunoreactive bands corresponding to 
HSP90. The figure presents the mean of two independent immunoblot-experiments, normalized to b-actin ± 
SD. The results are expressed relative to the control. Right side: representative blot of HepG2 protein lysate 
after HSP90 or b-actin antibody incubation.
Similarly to the regulation of HSP90, a time-dependent increase in HSP70 was detected in 
MTBITC-treated cells; however, over-expression of HSP70 did not occur until 6 h-
exposure of cells. For example, 24-h exposure of HepG2 cells resulted in a 170 %-increase 
in HSP70 expression above control. After 48 h, the densitometric analysis revealed a 220 
% elevation of protein level compared to control HepG2 cells. 
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Figure 36: Time-dependent over-expression of HSP70 after exposure of HepG2 cells with MTBITC at a 
concentration of 20 μM for 1-48 h. Lysate from HepG2 cells exposed to 0.1 % DMSO for 48 h were included 
as control. Left side: results of densitomentric scanning of the immunoreactive bands corresponding to 
HSP70. The figure presents the mean of three independent immunoblot-experiments, normalized to b-actin ± 
SD. The results are expressed relative to the control. Right side: representative blot of HepG2 protein lysate 
after HSP70 or b-actin antibody incubation.
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5.14 The telomere length of HepG2 cells is not rapidly decreased by MTBITC-
treatment
By probing the telomeric sequences of HepG2 cells with fluorochrome-tagged PNA probes 
and subsequent flow cytometric analysis, the length of HepG2 telomeres was assessed after 
MTBITC-treatment. This was particularly interesting, since it has been shown that rapid 
decrease in telomeric repeat sequences due to the uncapping of telomeres can precede 
apoptosis induction, or can be triggered due to apoptotic signals. But as presented in figure 
37, no significant alteration in the length of HepG2 telomeres could be observed within the 
full period of 48 h-treatment with MTBITC in a concentration of 20 μM. 
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Figure 37: Relative telomeric length (RTL) of 
HepG2 cells treated with 20 μM MTBITC for the 
indicated time points. Telomere length is 
expressed relative to the length of CCRF-CEM 
cells. The results are derived from three 
independent experiments. SC: solvent control = 
0.1 % DMSO
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5.15 MTBITC degrades rapidly in the  experimental system
To investigate the stability and degradation kinetics of MTBITC under the conditions of 
the cell culture studies, a set of experiments was carried out and the ITC subsequently 
analysed by GC-MS/MS. In all the experiments, MTBITC was applied at a final 
concentration of 10 μM, so that the results were comparable to the experiments already 
conducted with the cell culture. A rapid decrease of MTBITC could be observed within the 
first hour in culture flasks containing HepG2 cells adherent growing in culture medium 
(figure 38). During that time, a loss of 50 % MTBITC was detected in the extracted 
medium. After 6 h, only 25 % MTBITC remained in the medium and within 24 h MTBITC 
was no longer detectable. 
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Figure 38: Degradation kinetics of 10 μM MTBITC in filter capped culture flasks containing 1 x 106
adherent growing HepG2 cells in 5 ml culture medium. The change in concentration over time was 
detected by GC-MS/MS analysis. The figure depicts the mean of three independent experiments ± SD, 
expressed relative to the control.  
The experiment was repeated with the design differing only in the absence of HepG2 cells. 
As shown in figure 39, the kinetic of MTBITC degradation was similar to that derived with 
HepG2 cells. After 1 h, 50 % of the ITC was also degraded. 5 h later, 30 % was left in the 
medium and after 24 h,  MTBITC was depleted by 100 %.
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Figure 39: Degradation kinetics of 10 μM MTBITC in filter capped culture flasks containing  5 ml 
culture medium. The change in concentration over time was detected by GC-MS/MS analysis. The figure 
depicts the mean of two independent experiments ± SD, expressed relative to the control.  
0
20
40
60
80
100
120
0 200 400 600 800 1000 1200 1400 1600
Time [minutes]
M
TB
IT
C
 c
on
ce
nt
ra
tio
n 
[e
Distilled w ater w ith gas exchange
Figure 40: Degradation kinetics of 10 μM MTBITC in filter capped culture flasks containing 5 ml 
distilled water. The change in concentration over time was detected by GC-MS/MS analysis. The figure 
depicts the mean of two independent experiments ± SD, expressed relative to the control.  
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Analysis of MTBITC in the culture flasks containing distilled water instead of culture 
medium (figure 40) revealed that MTBITC was also degraded in the water in a time-
dependent manner, but the decrease of the ITC was 40 % and 70 % after 1 and 6 h, 
respectively. 24 h after experiment begin, 25 % of the ITC was still detectable.
In the last set of experiments, MTBITC was added to distilled water in tightly sealed 
culture flasks. The results are presented in figure 41. The prevention of gas exchange 
managed to maintain 10 % more MTBITC in the distilled water compared to unsealed 
culture flasks. Although the rapid decrease within the first hour was identical (40 %) to the 
previous experiments, but after 6h 50 % still remained in the distilled water. 
Figure 41: Degradation kinetics of 10 μM MTBITC in culture flasks containing 5 ml distilled water 
without gas exchange. To inhibit the gas exchange with the surrounding air, the culture flasks were tightly 
covered with parafilm. The change in concentration over time was detected by GC-MS/MS analysis. The 
figure depicts the mean of three independent experiments ± SD, expressed relative to the control.  
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5.16 Only early removal of MTBITC saves the cells from apoptosis
Early stages of p53-induced apoptosis may be reversible, as shown by Geske et al. (Geske 
et al., 2000) possibly due to the activation of DNA repair. However, the disruption of the 
MMP, is regarded to be an early, albeit already irreversible stage of apoptosis. If early 
stages of p53-induced apoptosis in MTBITC-treated HepG2 cells are indeed reversible 
through DNA repair, it is of interest to determine when the point of no return occurs in the 
cell system after MTBITC-exposure. These experiments were especially important, since it 
has been shown in human and in animal studies that the ITC decomposition rate is very 
high. Maximum levels are only present in these systems for rather a short time.  
Experiments were carried out to define the time point at which MTBITC-treatment of p53-
induced HepG2 cells had to be terminated to prevent the cells from apoptosis induction. 
Cells were treated for 1 h (the point at which only p53-induction was detectable) or 6 h 
(the point at which p53-induction plus MMP disruption were detectable) with 20 μM 
MTBITC, which was then thoroughly washed out and harvested at the time point 24 hours. 
The exposure of cells towards 0.1 % DMSO or 20 μM MTBITC for the whole period of 24 
h were used as controls. Figure 35 depicts the results of the effect on the MMP of HepG2 
cells, derived from three independent experiments, presented relative to the control. Figure 
36 displays the electrophoretic separation of internucleosomal DNA fragments of HepG2 
cells as a parameter for apoptosis induction. Interestingly, the privation of MTBITC after 1 
h saved the cells from a mitochondrial depolarization, which also prevented them from 
undergoing apoptosis. The "point of no return," beyond which MTBITC-exposure resulted 
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Figure 35: Determination of “the point of no-
return”: HepG2 cells were exposed to 20 μM 
MTBITC which was removed by washing after 1 or 
6 h. The MMP was assessed after 24 h. HepG2 cells 
exposed to 20 μM MTBITC for the whole length of 
24 h were used as reference control. The results are 
expressed relative to 0.1 % DMSO-treated cells. * P 
   3   VWDWLVWLFDOO\ VLJQLILFDQW
compared to control (N = 3)
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in irreversible progression to the loss of the MMP, occurred after exposure to 20 μM 
MTBITC for 6 h. At that point, the MMP was left to 5.34 % ± 1.17 compared to control 
cells. In relation to that, the MMP of HepG2 cells treated with MTBITC for the whole 24 h 
was diminished to 3.52 ± 1.08. 
In the DNA laddering assay, a distinct DNA fragmentation could be seen with cells treated 
with the positive control 6 μM CPT. No fragmentation could be observed in DNA derived 
from control or 1 h MTBITC-treated cells. 6-h treatment with MTBITC caused a weak but 
yet visible DNA ladder which intensified after the full length of 24 h-treatment with the 
ITC. 
Figure 36: Internucleosomal DNA 
fragmentation as parameter for apoptosis 
induction for the determination of “the point of 
no-return”: HepG2 cells were exposed to 20 μM 
MTBITC which was removed by washing after 1 or 
6 h. Electrophoretic DNA separation was then 
assessed at the time point 24 h. HepG2 cells 
exposed to 20 μM MTBITC for the whole length of 
24 h were used as reference control. M: size 
marker; SC: solvent control = 0.1 % DMSO; +: 
positive control = 6 μM CPT (N = 3).
  M     SC    -      1    6     24     +
Time [h]
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VI. DISCUSSION
6.1 DNA damage is an initial event in MTBITC-mediated growth inhibition
At the beginning of the study, the WST-1 assay and the analysis of protein content showed 
a concentration-dependent reduction in proliferation of HepG2 cells after MTBITC-
exposure. This was in accordance with other studies, which also reported inhibitory effects 
of ITCs on the growth of cancer cells in culture at μM-concentrations comparable with 
those at hand. For example, SFN, the structure analogue of MTBITC, inhibited the growth 
of colon cancer HT29 cells by 50 % at a concentration of 15 μM (Gamet-Payrastre et al., 
1998). Phenylethyl ITC (PEITC) also reduced the proliferation of HepG2 cells with an IC50
value of 17 μM (Xiao et al., 2003). Therefore, it is interesting to note that at these 
concentrations the ITCs did not influence the growth of non-cancer cells, which were also 
tested in the reported studies. The reason for this difference in response to ITC-treatment is 
probably based on the elevated stress level necessary for cancer cells to maintain their 
normal metabolic activity. Additional stress therefore results in a threshold crossing, which 
initializes the suicide program of the cancer cell. 
One of the earliest events in MTBITC-induced growth inhibition was probably a damaging 
effect on the DNA of HepG2 cells. This was already detected in the comet assay after 1 h-
exposure of HepG2 cells to MTBITC. It is proposed, that due to its electrophilic properties, 
MTBITC reacts readily with the nucleophilic sites of the DNA to cause damage. Although 
it has been proposed that ITCs can undergo spontaneous hydrolysis, leading to the 
formation of superoxide and H2O2, it is not very likely that ROS production is responsible 
for the genotoxic effect at this early stage since no increased level in oxidative stress could 
be detected at that time. Although, it should be noted that only the production of peroxides 
could be detected with DHR123. The fact that almost 50 % of MTBITC were degraded 
within only one hour also accounts for the high intra-system reactivity of the ITC. It can 
also be excluded that the increase in DNA migration after MTBITC-treatment at that time 
is due to apoptotic changes in the cells as has been proposed by Choucroun and his group 
(Choucroun et al., 2001) since there were no indications in the apoptosis specific assays. In 
an earlier study, Kassie et al. also reported DNA breaking effects of benzyl ITC and 
phenylethyl ITC in a HepG2 cell line with concentrations of 0(Kassie et al., 2003). 
However, the assay was terminated after 24 h-treatment of the cells with the ITCs. At that 
time point, the suicide program of the cells must have already been in progress and it 
cannot be excluded that their results were not at least influenced by apoptotic degradation 
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of DNA. It is known that the extent of DNA damage can also regulate the outcome. Low 
levels of DNA damage induce cell-cycle arrest, allowing the DNA damage to be repaired, 
and more extensive damage leads to the activation of the apoptotic process. It has been 
shown by our group that HepG2 cells can repair MTBITC-induced DNA damage to a 
certain extent (own data) and this might also be the reason for abrogation of apoptotic 
signs onto early removal of MTBITC (discussed later in this chapter); but at prolonged 
exposure towards MTBITC beyond this time, the DNA repair capabilities are obviously 
not sufficient to completely avoid the initialization of the apoptotic process.
6.2 MTBITC-induced apoptosis and G2/M arrest are downstream events of 
p53/p21WAF1
Apoptosis is a genetically controlled mechanism of cell death that is essential for cell 
population homeostasis and for the elimination of unwanted, i.e. damaged cells. In the 
presence of un-repaired chromosomal alterations, cells are prevented from entering into 
mitosis by the activation of certain checkpoints that ensure orderly and timely completion 
of such defects; however, in the case of severe damage, cell cycle arrest leads to apoptosis. 
It has been suggested that pathways to induce cell cycle arrest and apoptosis are 
simultaneously activated, but apoptosis is dominant to cell cycle arrest in cells competent 
to die (Shen and White, 2001). In the present study, MTBITC-induced apoptosis in HepG2 
cells could be observed by internucleosomal DNA fragmentation, flow cytometry analysis 
and the detection of single stranded apoptotic DNA. In all three assays, clear apoptotic 
events were present after 6 h-exposure to 20 μM MTBITC. Other studies have shown that 
although the group of ITCs are rather similar in structure, the time point of detectable 
apoptotic changes varies as well as the necessary concentration for its induction. In 
comparison to the results in the present study, HepG2 cells treated with 20 μM PEITC 
were TUNEL- and “SubG1-content” negative after 6 h, but stained positive after 12 h. 
However, caspase-3-like activity already significantly increased after 1 h (Rose et al., 
2003). At a concentration of 20 μM, PEITC did not affect the cell cycle of HepG2 cells in 
their study; a G2/M phase-arrest could only be detected at 5 and 10 μM. This arrest was as 
early as 6 h and non-persistent at 5 μM, but irreversible at 10 μM PEITC-treatment. In the 
present study, 60 % of the HepG2 cells were caused to arrest by MTBITC at the G2/M 
phase of the cell cycle within the first 24 h, beginning at the same time as typical apoptotic 
features became evident and persisting for at least 24 h. This conforms to the observed 
reduction in the metabolic activity of HepG2 cells after 24 h, which remained static over a 
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prolonged time. Also, light-microscopic survey of the cells exposed to MTBITC for 48 h 
and 72 h (data not shown) did no show any further increase in detached, apoptotic cells, 
but a hold-up in cell number. All this would argue for a continuing arrest of more than 24 
h. However, since no analysis of DNA content distribution was conducted for more than 24 
h, it is for speculation whether the cells remained arrested or were also subsided to 
apoptotic death later on.  
The decision between promoting cell cycle arrest versus apoptosis partially relies on the 
p53 protein level. Wild-type p53 is a sequence specific transcription factor mediating 
downstream effects such as cell cycle arrest or apoptosis in response to a variety of stress 
signals, including DNA damage, oncogene activation and hypoxia (Oren, 2003). Whereas 
high levels of p53 correlate with apoptosis, low level expression of the protein leads to cell 
cycle arrest. Furthermore, the proportion of arrested cells depends on cell type, growth 
conditions and the checkpoint controls operative in the cell (Niculescu et al., 1998). In the 
present study, increased expression of p53 and its family member p63 was observed in 
HepG2 cells after MTBITC-treatment in a time-dependent manner. This corresponds to a 
study recently published by Fimorgnari and co-workers, who reported an increase in p53 
protein expression after 8 h of MTBITC-treatment in a concentration of 10 μM. This p53 
stabilization was followed by a prolonged arrest of Jurkat cells at the G2 phase (Fimognari 
et al., 2004b). In the present study, the stabilized expression of p53 is reckoned to be a 
direct response to the chromosomal damage observed at the same time in the comet assay. 
It has been shown, that DNA single strand breaks lead to the DNA binding and consecutive 
stabilization of p53, which controls a G2 checkpoint upstream of p21WAF1(Bunz et al., 
1998). Shortly after the stabilization of p53, an increase in p21WAF1 protein expression was 
observed in the study at hand, which was clearly stabilized 6 h after chemical treatment. 
p21WAF1 is mainly reported as a mediator for the arrest of cells at the G1 phase, but it has 
also been shown to inhibit proliferation at the G2/M phase. Especially after DNA damage, 
p21WAF1 is essential to sustain the G2 checkpoint in human cells (Gartel and 
Radhakrishnan, 2005). After 24 h-exposure of HepG2 cells to MTBITC, p53 was 
suppressed, probably by the activation of MDM2. It is known that high levels of MDM2 
by increased p53 activity generates an auto-regulatory loop that leads to rapid turnover of 
the p53 protein, allowing induced p53 to act during a short time window before it is 
withdrawn to its normal cellular levels (Haupt et al., 1997; Kubbutat et al., 1997).
On the contrary, p63 was not degraded after MDM2 activation. Recent studies indicate the 
importance of the interaction between p63 and p53 in controlling the function of p53 
VI. Discussion                                                                                                                       74
during cellular death. It has been proposed that DNA damage not only recruits p53, but 
also p63, initializing the mitochondrial mediated-death pathway (Gressner et al., 2005). 
Although the members of the p53 family share a lot of gene regions, p63 is not destabilized 
by MDM2. p63 is able to physically interact with MDM2 in that way, increasing the 
steady-state level of intracellular p63 and enhancing its transcriptional activity (Calabro et 
al., 2002). Calabro and co-workers proposed that MDM2 expression could support p63-
specific transcriptional function, while at the same time reducing interference by p53. 
These observations are consistent with the present findings that after MTBITC-treatment, 
p63 is immediately activated but then remains on a basal expression level. However, the 
level dramatically increases with the activation of MDM2 after 6 h, indicating for an 
MDM2-mediated stabilization of p63 rather than degradation.
p63 protein has already been shown to contribute to chemical-induced apoptosis, but this is 
the first time the involvement of p63 in ITC-induced apoptosis is reported in a study. The 
exact role and relevance of p63 in ITC-mediated cell death has yet to be determined in 
further studies. Like p53, p63 may simultaneously recruit genes, acting additively or 
synergistically in the ITC-mediated suicidal death. This protein might be especially 
interesting due to its prolonged activation and further stabilisation by MDM2 during the 
growth suppression of the hepatoma cells.
6.3 Glutathione depletion and the production of ROS in HepG2 cells
The loss of GSH may impair cellular antioxidant defences, resulting in the accumulation of 
ROS (Tirmenstein et al., 2000). These are generated as by-products of normal cellular 
function, mainly mitochondrial respiration or cytochrome P450, but are also found as 
downstream mediators of enhanced p53 expression in the apoptotic process (Johnson et al., 
1996; Li et al., 1999). Hall  proposed oxidative stress as a trigger of the apoptotic process, 
whereas GSH depletion renders cells more susceptible to oxidative damage (Hall, 1999).
This, in consequence, may initialize signal transduction for the induction of programmed 
cell death. 
In the present study, significant depletion of GSH occurred after 6 h-exposure to MTBITC 
in a concentration of  20 μM. This GSH depletion was persistent over at least 24 h and 
not temporarily as reported by Ye and Zhang (Ye and Zhang, 2001). As stated above, 
MTBITC is assumed to react with nucleophiles, especially those that contain a sulphur 
moiety like GSH. It has been reported that ITCs readily and strongly bind to GSH, a 
mechanism which is made responsible for the fast accumulation of ITCs within the cell. 
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Zhang reported a 200-fold total intracellular accumulation of SF or BITC as GSH-
conjugates in murine Hepa1c1c7 cells compared to the extra-cellular level within 30 min. 
This accumulation resulted in a depletion of intracellular GSH by 50 % (Zhang, 2001).
Similar effects were reported by other authors (Zhang, 2000). The loss of GSH may then 
allow critical protein thiol groups, e. g. the inner mitochondrial adenine nucleotide 
translocase (ANT), to be alkylated, which in turn results in the formation of oxidative 
stress (Hudson et al., 2005; Kim et al., 2003; Xu and Thornalley, 2001). Hepatic 
mitochondria are especially vulnerable to the accumulation of ROS since they lack the 
H2O2-metabolizing enzyme catalase. This concurs with the present study, where a 
significant amount of ROS (i.e. predominantly peroxides), could be observed in parallel to 
the exhaustion of the GSH supplies and the beginning collapse of the MMP. Taking into 
account that the detected oxidative stress generation was a) significant, but rather weakly 
elevated compared to other studies and b) detectable at the same time of early apoptotic 
events, it is likely, that the monitored oxidative stress was due to leaking from damaged 
mitochondria rather than preceding the apoptotic cascade as suggested by Hall. It is also 
possible that the rise in peroxide level contributes as p53 downstream effector, as proposed 
earlier (Tirmenstein et al., 2000), although it should be mentioned that in their study, ROS 
were generated concomitantly with increased levels of p53 and the onset of apoptosis. In 
contrast, the peroxide production significantly elevated not until 6 h-treatment of HepG2 
cells in the study at hand, despite a p53-stabilization after 1 h. 
It also remains to be determined whether superoxides (*O) account for apoptosis 
initialisation by MTBITC as has been reported for PEITC in HepG2 cells (Rose et al., 
2003). Significant *O production was reported in their study to occur as early as 1 h in 
PEITC-treated HepG2 cells. In contrast to the present study, the authors did not detect 
increased peroxide generation during PEITC-exposure, however their measurement ranged 
only from 0.25 to 3 h after treatment begin, which might have been too short for the 
peroxide detection. On the other hand, it should be taken into consideration that *O are 
rapidly converted by enzymes like e.g. superoxide dismutase (SOD) to H2O2 which is more 
stable than *O. Therefore, extensive *O-production would have been expected to be 
indirectly detectable with the H2DCFDA assay, applied in their study or DHR123 used in 
the present study. In PC-3 cells, for example, PEITC already induced both peroxide and 
*O-production after 1 h, whereas apoptosis induction was not detectable before 4 h, 
indicating an upstream-function of ROS in these cells (Xiao et al., 2006)
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6.4 The intrinsic mitochondrial-dependent pathway contributes mainly to MTBITC-
induced apoptosis 
Dissipation of the mitochondrial membrane potential is a general feature of apoptosis, 
irrespective of the cell type and of the apoptosis inducer. Whenever a pharmacological or 
genetic manipulation succeeds in preventing apoptosis, it also abolishes the MMP
disruption that usually precedes cytolysis. The MMP collapse constitutes an early event of 
apoptosis; nonetheless, it marks an already irreversible stage of the apoptotic process. 
Massive loss in mitochondrial integrity caused by ITCs has been reported by several 
authors. For example, Rose and co-workers (Rose et al., 2005) reported severe 
mitochondrial damage after exposure of HepG2 cells to 20 μM PEITC for only 15 min. In 
these studies it was proposed that the collapse of the MMP was due to the massive 
production of ROS by ITCs, exerting downstream signalling onto the mitochondria. 
Interestingly, a severe loss in the mitochondrial membrane integrity was not observed in 
the present study until 6 h of exposure of HepG2 cells to 20 μM MTBITC. The beginning 
collapse of the MMP was accompanied by the suppression of BclXL, which exerts critical 
anti-apoptotic function by stabilizing the outer mitochondrial membrane and preventing the 
release of death factors (Huang and Strasser, 2000). As already discussed above, peroxide 
production was a late event in the present study and is considered to originate from within 
the mitochondria. But the confirmation of BclXL-suppression allows to suggest yet a further 
possibility of cell death signalling besides the already discussed: it has been shown earlier, 
that over-expression of BclXL suppresses p53-dependent cell death. Additionally, recent 
evidence has proposed the existence of a transcription-independent pathway of p53-
mediated apoptosis. In this process, a fraction of the p53 molecules that accumulate in 
damaged cells translocates to mitochondria, and this translocation is sufficient for p53 to 
induce permeabilization of the outer mitochondrial membrane through formation of 
complexes with the protective proteins BclXL and Bcl2, resulting in the release of 
cytochorme c into the cytosol (Mihara et al., 2003; Mihara and Moll, 2003). So, whether 
the collapse of the MMP by MTBITC could be mediated indirectly through ROS or 
directly by p53 must be elucidated more closely in future research.
6.5 MTBITC successfully suppressed telomerase in HepG2 cells
For a long time, the approaches in telomerase research and its suppression as a potential 
new way in selective chemotherapy of cancer only focused on the theory that abrogation of 
its enzyme activity leads to the successive shortening of telomeres, finally resulting in 
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cellular crisis and senescence. So reports dealing with the suppression of telomerase in the 
presence of reduced cell viability were eyed critically and simply labeled “cytotoxic effects 
caused by chemical treatment”. For example, in a study by Holt et al. a 5-fold decrease in 
telomerase-activity after treatment of HT1080 and SW480 cells with the G2/M blocker 
doxorubicin was reported (Holt et al., 1997). However, this was accompanied by a large 
amount of cell death after 12 to 16 h. Nocodazole-treated cells also showed a 2.5-fold 
decrease in telomerase activity compared to control cells, but also contained 2-fold less 
protein per cell than the control population. Faraoni et al. evaluated the general 
applicability of telomerase activity measurement as a marker of chemotherapy failure in 
telomerase-positive tumor cells (Faraoni et al., 1997). The authors showed a clear 
correlation between the decline of telomerase activity and the antineoplastic agent-induced 
growth impairment of tumor cells. However, in their experiments, 50 % of the tumor cells 
were already suppressed by chemical treatment after 24 h, approaching 100 % suppression 
another 48 h later. Only very recently, it was concluded that telomerase regulation was not 
simply a matter of the enzymatic activity but that the catalytic subunit hTERT affects cell 
cycle regulation. Although conflicting information is available about the connection 
between the cell cycle of cancer cells and telomerase, some studies demonstrated that 
telomerase activity was constant during progression through the cell cycle stages of several 
immortal cultured cells and generally correlates with growth rate (Holt et al., 1997); others 
show an increase during the S phase of artificially arrested cells (Zhu et al., 1996). It 
seems, the analysis of telomerase depends upon the nature of cell-cycle perturbation, cell 
type and experimental design. Akiyama and co-workers investigated the influence of the 
anti-SUROLIHUDWLYHDJHQWLQWHUIHURQĮ,)1-ĮRQWHORPHUDVHDQGLWVFRQVWLWXHQWV(Akiyama et 
al., 1999). These investigations were performed by a halt of cell cycle progression, rather 
than progression from the resting state. They found telomerase activity and hTERT 
expression independent from the cell cycle of untreated Daudi cells but after IFN-Į –
treatment, a suppression of the enzyme activity in the cells accumulated at the G1 phase. 
The role of hTERT in the regulation of the cell cycle and its importance in the vulnerability 
to drug-induced apoptosis is not well understood. But, it has been shown by Biroccio et al. 
that the ability of hTERT-positive human melanoma cells to recover from drug-induced 
damage was attributable to the restoration of cell cycle progression (Biroccio et al., 2003).
In contrast to hTERT negative cells which were arrested irreversible at the G2/M phase of 
the cell cycle after chemical-treatment, hTERT-positive cells were saved of this G2/M 
block. The reconstitution of hTERT in these melanoma cells resulted in a decreased 
VI. Discussion                                                                                                                       78
number of total chromosomal end-to-end fusions rendering cells less sensitive to chemical 
induced apoptotic death. The persistence of structural chromosomal lesions was evident 
only in hTERT negative cells, treated with drugs.
In HepG2 cells, a suppression of hTERT protein by 50 % compared to control could be 
detected 24 h after exposure to MTBITC. At this time point, a maximal number of arrested 
cells at the G2/M phase and all typical features of apoptosis were observed. Telomerase 
enzyme activity was also significantly suppressed after 24 h, detected by the TRAP assay. 
These changes occurred without any detectable rapid shortening in telomere length of 
HepG2 cells. This corresponds to a study by Cao et al., who proposed a pro-survival, anti-
apoptotic role of hTERT aside from its telomere elongating function in PMC42 breast 
cancer cells (Cao et al., 2002). In their study, down-regulation of hTERT resulted in 
apoptosis induction without telomere-shortening. Other authors also reported anti-
apoptotic properties of hTERT, proposing a telomere capping function of telomerase, 
independently from the telomere elongation function (Blackburn, 2000). It seems that in 
MTBITC-treated HepG2 cells, the telomerase catalytic subunit also regulates cell survival 
besides its enzymatic role and that hTERT suppression might indeed be initialized by the 
activation of p53, as hypothesized. The downstream effect of p53-transactivation of the 
p21-promotor represents the negative modulator of the cell cycle, preventing progression 
past the G2/M checkpoint. It was reported by Lai and co-workers (Lai et al., 2007) that the 
activation of p21WAF1 leads to the repression of the hTERT promotor, thereby effectively 
shutting down the cell cycle. In their study, hTERT exerted effects on its upstream 
regulators, p53 and p21, thereby partially regulating itself. Additionally, it has been shown 
that over-expression of  p21WAF1 induces the suppression of hTERT in human squamous 
cell carcinoma (Henderson et al., 2000) and glioma cells (Harada et al., 2000) which both 
abnormally express telomerase. This is in accordance to the present study, where the 
suppression of hTERT occurred after the activation of p21WAF1, suggesting an indirect path 
of telomerase regulation besides the earlier proposed  SP1 squelching for hTERT promoter 
repression (Xu et al., 2000). This telomerase suppression, mediated by the p53/p21/E2F 
pathway was already reported by Shats and his group (Shats et al., 2004).
Since MTBITC-induced apoptosis was mediated by the mitochondrial-death pathway, a 
migration of hTERT from the nucleus to the mitochondria could additionally play a role in 
MTBITC-mediated cell death. hTERT could thereby amplify the oxidative load in the 
mitochondria and result in increased damage to the mitochondrial DNA. This mechanism 
was proposed by Haendeler et al., who showed that H2O2 triggers the nuclear export of 
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hTERT, which dramatically increased the sensitivity of cells towards ROS-dependent 
apoptosis in their study (Haendeler et al., 2003). It will be a challenge for future research to 
elucidate these possible mechanistic pathways of hTERT regulation in growth inhibition 
by ITCs.
6.6 The HSP90 complex might stabilize the telomerase holenzyme
The time lag between the treatment begin of HepG2 cells with MTBITC and an observable 
suppression of telomerase is consistent with the reported long half-life of the functionally 
active enzyme (Holt et al., 1997). Telomerase activity appears to be highly stable with a 
half-life of > 24 h in a variety of cell lines. A number of studies reported a 12 to 48 h 
lasting delay between the downregulation of hTERT mRNA and the decrease in telomerase 
activity. For example, Shats et al. observed a significant p53-dependent reduction of 
hTERT mRNA 18 h post-treatment using real-time quantitative RT-PCR (Shats et al., 
2004). A decline in the enzyme activity, however, did not occur before 48 h. It is proposed 
that in the present study an improved assembly of the remaining hTERT protein to the 
functionally active enzyme by the HSP complex resulted in a delayed activity decay and 
provided for an increased half-life of the telomerase enzyme, as so proposed by Akalin and 
co-workers (Akalin et al., 2001). Immunoblot-analysis revealed a strong, prolonging 
increase in the heat shock proteins HSP90 and HSP70 after MTBITC-treatment. The 
HSP90 chaperone complex, including p23, HSP90 and HSP70 is known to facilitate the 
folding of several reverse transcriptases. By forming conformation-dependent high-order 
chaperone complexes, HSP90 regulates the half-lives of its client proteins (Johnson et al., 
1998). It was proposed earlier by Holt et al. that this complex is strongly required to allow 
functional association of the telomerase enzyme both in vitro and in vivo (Holt et al., 
1999). The authors showed that HSP90 binds to hTERT, the blocking of this interaction 
inhibited the assembly of telomerase. Furthermore, after the addition of purified
chaperones in an in vitro P69 prostate cell reconstitution system, telomerase activity 
dramatically increased, suggesting a significant proportion of telomerase being unfolded or 
unassembled in cells, possibly due to inadequate chaperone expression (Akalin et al., 
2001).
6.7 Despite its rapid degradation, MTBITC could exert sufficient therapeutic effects
Disposal kinetics of ITCs have already been performed in animals (Ioannou et al., 1984)
and humans (Ji and Morris, 2003). Also, the metabolic conversion of several ITCs have 
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been elucidated in cell culture systems or in animals (Zhang, 2000) . However, as yet, no 
efforts have been made to determine the kinetics of ITCs in the in vitro models at hand. To 
investigate the stability and kinetics of MTBITC under the conditions of the cell culture 
studies, and to learn more about the origin of the ITC-decomposition, a set of experiments 
was carried out and the ITC subsequently analysed by GC-MS/MS. The present kinetic 
studies of MTBITC in the cell culture system showed that the ITC degraded within the first 
hour by 50 % and was totally absent (i. e. below the detection limit) after 24 h. At first, the 
metabolic conversion of MTBITC by the hepatoma cells was thought to be solely 
responsible since the analysis covered only the ITC and not the metabolites. Zhang et al. 
showed that ITCs are rapidly converted to their thio-derivatives in vitro and in vivo
(Zhang, 2000). However, the next set of experiments, repeated in the same line but without 
cells, revealed that only around 10 % could be attributed to the metabolic activity of 
HepG2 cells. The reactivity and volatility of ITCs was already noted above. ITCs react 
rapidly, and under mild conditions with oxygen-, sulfur-, or nitrogen centered nucleophiles 
to give rise to carbamates, thiocarbamates, or thiourea derivatives, respectively (Zhang and 
Talalay, 1994). Ohta and his group showed that allyl ITC is highly unstable in aqueous 
solution, its decomposition by the nucleophilic attack of water or even more of hydroxide 
ions against the ITC group being rapid (Ohta et al., 1995).  A study by Sommerlade and 
co-workers dealing with the behaviour of ITC in atmospheric surroundings demonstrated 
that ITCs react intensely with OH radicals to form a variety of different conversion 
products, which are mainly isocyanates and sulfur dioxide (Sommerlade et al., 2006). Jiang 
and his group (Jiang et al., 2006) confirmed later the fact that the reaction between ITC and 
hydroxyl/water was endothermic, thus in vitro experiments, normally carried out at 37°C, 
always present extreme unfavorable conditions for the ITC. MTBITC differs structurally 
only slightly from allyl ITC, therefore, the vast amount of MTBITC degradation is 
possibly due to its reactivity with the surrounding aqueous material. Additionally, the 
autolysis of MTBITC to its isocyanate-derivative could also account for the observations. 
Loss by simple diffusion of the volatile MTBITC out of the culture flask is therefore 
thought to constitute for around 10 % of the total. About 25 % might be attributed to the 
reaction of MTBITC with thiol-containing amino acids (e.g. methionine) or larger proteins 
in the culture medium. Albumin for instance, which is also supplemented to the culture 
medium, has been proposed to be the main transporting molecule of ITCs within the blood 
system  (Holst and Williamson, 2004) and a docking of MTBITC to such a protein in the 
medium would indeed result in a decreased  extraction result. 
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These findings are all the more intriguing considering the rapid loss in MTBITC on the one 
hand, and the strong cytostatic effect of the ITC on the other. This suggests that 
irrespective of the intense degradation kinetics of MTBITC, the anti-proliferative activity 
and the potency in apoptosis induction is not markedly affected by it. 
It has been suggested that early stages of p53-induced apoptosis may be reversible upon 
removal of the apoptosis stimulus due to DNA repair initialization (Geske et al., 2000). 
The reversibility of MTBITC-induced death of HepG2 hepatoma cells was tested at the 
initiation phase (DNA damage after 1 h) and at the commitment/degradation phase 
(beginning MMP collapse after 6 h) which showed that the apoptotic process may only 
indeed be reversible or at least weakened at the very early stages upon a removal of 
MTBITC. It was also shown in a study by Zhang et al. that exposure to ITCs for only a 
short time of one or three hours was sufficient to irreversibly inhibit cell growth (Zhang et 
al., 2003). In vivo, ITCs are metabolised and excreted within 24 h with a blood plasma 
peak concentration during the first 2 to 6 h. Thus, although the ITC is only present at 
maximum concentrations in a living system for a rather short time, this might be sufficient 
to exert its therapeutic effects. 
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Figure 42: Time scheme of the events detected in HepG2 cells after exposure to MTBITC for 1 to 48 h 
and proposed signalling pathways.  indicate the initial interaction of MTBITC with GSH or the DNA.
 was used to indicate an activating event. ŏ was set for a proposed blocking/destabilizing mechanism.
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6.8 Conclusions
This study presents for the first time the suppression of telomerase in malignant cells 
mediated by ITCs. MTBITC-treatment of HepG2 cells could successfully down-regulate 
telomerase, either through transcriptional suppression of hTERT by p53 or through an 
indirect p21WAF1-dependent pathway. The present findings support the idea of an existing 
extra-telomeric, cell cycle regulation function of hTERT in HepG2 cells. Thus, DNA 
damage induced by MTBITC is proposed to present the initial event leading to p53-
activated cell cycle arrest and apoptosis induction in these cells. Whether p63 promotes 
stabilization of p53 and which contribution p63 generally makes in hTERT suppression has 
to be further explored. The role of telomerase in ITC-mediated growth suppression of 
malignant cells will now have to be elucidated more closely and its general contribution in 
ITC-mediated apoptosis induction and cell proliferation clarified. This information may 
help for a better understanding of the role of telomerase and could be valuable in 
improving the effectiveness of future therapeutic interventions.
6.9 Future perspectives
In an actual study in our lab, MTBITC and several other structure analogues have been 
shown to exert also positive results in the micronucleus (MN) test, carried out with HepG2 
cells. The MN test is a biomarker of chromosomal instability, whereas the detected MNs 
are due to the exclusion of chromosomes or chromosomal fragments from daughter nuclei 
(Fenech, 2005). The results of the present study raise the question, whether this 
genotoxicity observed with the MN test in HepG2 cells after the ITC-treatment is at least 
partly due to the detection of end-to-end fusions, initialized by the suppression of hTERT, 
which consequently resulted in the loss of telomere capping. As already stated, HepG2 
cells possess only short telomeres and are therefore very susceptible for chromosomal 
alterations. This becomes especially apparent in the MN test, where it has been shown, that 
HepG2 cells exert a rather high rate in the spontaneous formation of micronuclei, 
compared to other cell lines. For this reason, it would be intriguing to find out, if the 
increased frequency of MNs observed after cell-treatment with ITCs, origins from the 
exclusion of telomeric sequences. This would shed a new light on the meaning of positive 
results in the MN test derived from experiments with ITCs. 
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XI. APPENDIX
Table 13: Proliferation of HepG2 cells assessed with the WST1 assay after 24 h
C SC 1 μM 3 μM 10 μM 20 μM 30 μM
Test 1 0,69 0,67 0,67 0,57 0,52 0,36 0,34
Test 2 0,6 0,53 0,46 0,51 0,48 0,48 0,34
Test 3 0,64 0,59 0,64 0,66 0,66 0,42 0,39
mean 0,64 0,60 0,59 0,58 0,55 0,42 0,36
std. dev. 0,05 0,07 0,11 0,08 0,09 0,06 0,03
Table 14: Proliferation of HepG2 cells assessed with the WST1 assay after 48 h
C SC 1 μM 3 μM 10 μM 20 μM 30 μM
Test 1 1,61 1,45 1,59 1,61 1,16 0,65 0,39
Test 2 0,97 0,85 0,91 1,08 0,99 0,53 0,36
Test 3 1,1 0,92 1,25 1,13 1,23 0,72 0,38
mean 1,23 1,07 1,25 1,27 1,13 0,63 0,38
std. dev. 0,34 0,33 0,34 0,29 0,12 0,10 0,02
Table 15: Proliferation of HepG2 cells assessed with the WST1 assay after 72 h
C SC 1 μM 3 μM 10 μM 20 μM 30 μM
Test 1 1,89 2,25 2,23 2,58 2,56 1,37 0,29
Test 2 1,84 1,61 1,75 1,94 1,75 0,78 0,27
Test 3 1,6 2,05 2,28 2,38 2,44 1,07 0,28
mean 1,78 1,97 2,09 2,30 2,25 1,07 0,28
std. dev. 0,16 0,33 0,29 0,33 0,44 0,30 0,01
Table 16: Protein concentration (μg/μl) of HepG2 cells exposed to 20 μM MTBITC for the indicated 
time points
SC 24 h 48 h 72 h
Test 1 3,4 2,78 1,34 0,25
Test 2 4,71 3,26 1,57 0,26
Test 3 4,38 3,4 1,46 0,42
Test 4 4,32 3,5 1,23 0,19
mean 4,20 3,24 1,40 0,28
std. dev. 0,56 0,32 0,15 0,10
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Table 17: Induction of apoptosis assessed by the "subG1" DNA content of HepG2 cells after 
MTBITC-treatment for 24 h
SC 5 μM 10 μM 20 μM 30 μM 50 μM + control
Test 1 2,29 2,71 5,64 15,28 11,03 3,95 13,92
Test 2 2,46 2,61 7,14 15,02 8,22 3,53 17,67
Test 3 2,68 3,43 4,93 17,78 14,69 3,7 17,31
mean 2,48 2,92 5,90 16,03 11,31 3,73 16,30
std. dev. 0,20 0,45 1,13 1,52 3,24 0,21 2,07
Table 18: Apoptosis induction, assessed by the detection of ssDNA
SC 1 h 3 h 6 h 24 h + control IC
Test 1 0,29 0,14 0,12 0,48 0,6 1,27 1,59
Test 2 0,35 0,25 0,33 0,48 0,74 1,52 1,67
Test 3 0,28 0,36 0,3 0,36 0,6 1,52 1,64
mean 0,31 0,25 0,25 0,44 0,65 1,44 1,63
std. dev. 0,04 0,11 0,11 0,07 0,08 0,14 0,04
Table 19: Cell cycle distribution of HepG2 cells after 1 h-treatment with MTBITC
Cell cycle phase 
G1 S G2/M
Test 1 SC 72,2 19,64 8,15
Test 2 SC 71,23 19,29 9,48
Test 3 SC 70 20,97 9,03
mean 71,14 19,97 8,89
std. dev. 1,10 0,89 0,68
Test 1 20 μM 75,56 15,68 8,76
Test 2 20 μM 74,69 15,5 9,81
Test 3 20 μM 74,28 15,44 10,28
mean 74,84 15,54 9,62
std. dev. 0,65 0,12 0,78
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Table 20: Cell cycle distribution of HepG2 cells after 3 h-treatment with MTBITC
Cell cycle phase 
G1 S G2/M
Test 1 SC 74,99 15,67 9,35
Test 2 SC 61,02 27,49 11,49
Test 3 SC 59,53 30 10,47
mean 65,18 24,39 10,44
std. dev. 8,53 7,65 1,07
Test 1 20 μM 73,85 14,4 11,75
Test 2 20 μM 71,09 14,88 14,03
Test 3 20 μM 75,81 11,02 13,17
mean 73,58 13,43 12,98
std. dev. 2,37 2,10 1,15
Table 21: Cell cycle distribution of HepG2 cells after 6 h-treatment with MTBITC
Cell cycle phase 
G1 S G2/M
Test 1 SC 74,73 18,52 6,75
Test 2 SC 74,48 20,02 5,5
Test 3 SC 74,61 19,3 6,08
mean 74,61 19,28 6,11
std. dev. 0,13 0,75 0,63
Test 1 20 μM 65,65 15,99 18,35
Test 2 20 μM 67,15 9,13 23,73
Test 3 20 μM 66,15 9,08 24,77
mean 66,32 11,40 22,28
std. dev. 0,76 3,98 3,45
Table 22: Cell cycle distribution of HepG2 cells after 24 h-treatment with MTBITC
Cell cycle phase 
G1 S G2/M
Test 1 SC 70,63 19,5 9,87
Test 2 SC 67,75 21,9 10,54
Test 3 SC 67,56 21,73 10,52
mean 68,65 21,04 10,31
std. dev. 1,72 1,34 0,38
Test 1 20 μM 24,87 13,35 61,78
Test 2 20 μM 25,73 15,79 58,48
Test 3 20 μM 28,55 13,44 58,01
mean 26,38 14,19 59,42
std. dev. 1,93 1,38 2,05
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Table 23: Expression of p21WAF1 in HepG2 cells after Exposure to 20 μM MTBITC for the indicated 
time points (% of control)
Time (h) Test 1 Test 2 mean std. dev.
1 7,43 0,00 3,71 5,25
3 6,53 11,72 9,13 3,67
6 32,05 31,09 31,57 0,68
24 29,15 69,28 49,21 28,37
48 34,93 58,64 46,79 16,77
Table 24: GSH level of HepG2 cells after treatment with MTBITC for 6 h
Test 1 GSH (μM)
% of 
control Test 2 GSH (μM)
% of 
control mean std. dev.
DMSO 0,79 14,07 100,00 0,77 13,64 100,00 100,00 0,00
1 μM 0,97 17,43 123,89 1,02 18,22 133,64 128,77 6,90
3 μM 1,13 20,19 143,46 1,11 19,96 146,36 144,91 2,05
10 μM 1,08 19,40 137,85 0,97 17,44 127,87 132,86 7,06
20 μM 0,36 6,14 43,66 0,32 5,46 40,07 41,86 2,54
30 μM 0,37 6,42 45,59 0,30 5,10 37,38 41,48 5,81
50 μM 0,14 2,14 15,19 0,12 1,80 13,22 14,20 1,39
Table 25: GSH level of HepG2 cells after treatment with MTBITC for 24 h
Test 1 GSH (μM)
% of 
control Test 2 GSH (μM)
% of 
control mean std. dev. 
DMSO 0,31 5,41 100,00 0,33 5,75 100,00 100,00 0,00
1 μM 0,50 8,72 161,22 0,56 9,95 173,00 167,11 8,34
3 μM 0,67 11,82 218,68 0,74 13,24 230,30 224,49 8,21
10 μM 0,60 10,60 196,15 0,75 13,26 230,66 213,41 24,40
20 μM 0,04 0,47 8,64 0,09 1,23 21,36 15,00 8,99
30 μM 0,02 -0,06 0,00 0,04 0,32 5,51 2,75 3,89
50 μM -0,04 -1,01 0,00 0,02 0,05 0,87 0,44 0,62
Table 26: MMP of HepG2 cells after valinomycin-treatment for 24 h (% of control)
0,1 μM 1 μM 10 μM 100 μM
Test 1 42,98 20,34 17,30 9,05
Test 2 59,43 32,31 22,86 9,51
Test 3 39,83 17,26 8,11 8,41
mean 47,42 23,30 16,09 8,99
std. dev. 10,53 7,95 7,45 0,55
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Table 27: MMP of HepG2 cells after MTBITC-treatment for 3 h (% of control)
3 μM 10 μM 20 μM 30 μM + control
Test 1 113,36 94,80 103,15 93,92 26,78
Test 2 107,31 92,64 82,92 101,71 64,72
Test 3 88,47 89,87 87,91 83,36 36,52
mean 103,05 92,44 91,33 93,00 42,67
std. dev. 12,98 2,47 10,54 9,21 19,70
Table 28: MMP of HepG2 cells after MTBITC-treatment for 6 h (% of control)
3 μM 10 μM 20 μM 30 μM + control
Test 1 82,67 121,00 74,70 60,78 17,01
Test 2 111,66 104,63 84,37 33,86 6,65
Test 3 70,37 94,01 83,79 71,87 24,54
mean 88,23 106,55 80,95 55,50 16,07
std. dev. 21,20 13,60 5,42 19,55 8,98
Table 29: MMP of HepG2 cells after MTBITC-treatment for 24 h (% of control)
3 μM 10 μM 20 μM 30 μM + control
Test 1 72,90 29,63 5,43 8,47 8,81
Test 2 58,40 39,48 5,48 8,75 10,69
Test 3 90,57 57,24 14,44 6,22 12,45
mean 73,96 43,44 8,45 7,81 10,65
std. dev. 16,11 19,52 5,19 1,39 1,82
Table 30: Expression of Bclxl in HepG2 cells after Exposure to 20 μM MTBITC for the indicated 
time points (% of control)
Time (h) Test 1 Test 2 Test 3 mean std. dev.
1 h 125,49 105,59 85,08 114,39 34,56
3 h 152,26 59,82 57,80 89,96 53,96
6 h 56,72 45,70 15,41 39,27 21,39
24 h 44,87 56,27 22,65 41,26 17,09
48 h 40,00 56,27 37,21 44,49 10,29
Table 31: Conversion of 5 μM DHR123 to RH123 in HepG2 cells by H2O2 (% of control)
Test 1 Test 2 mean std. dev.
10 μM 79,98 65,67 72,83 10,12
30 μM 223,90 191,70 207,80 22,77
100 μM 620,12 531,94 576,03 62,35
300 μM 1612,35 1376,19 1494,27 166,99
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Table 32: Conversion of 10 μM DHR123 to RH123 in HepG2 cells by H2O2 (% of control)
Test 1 Test 2 mean std. dev.
10 μM 89,65 68,05 78,85 15,27
30 μM 247,92 186,24 217,08 43,61
100 μM 639,10 508,90 574,00 92,07
300 μM 1636,51 1297,34 1466,92 239,83
Table 33: Conversion of 50 μM DHR123 to RH123 in HepG2 cells by H2O2 (% of control)
Test 1 Test 2 mean std. dev.
10 μM 76,79 61,20 68,99 11,02
30 μM 207,70 152,74 180,22 38,87
100 μM 527,95 405,43 466,69 86,64
300 μM 1065,19 818,58 941,88 174,38
Table 34: Production of ROS in HepG2 cells exposed to MTBITC for 1 h (% of control)
Test 1 Test 2 Test 3 Test 4 mean std. dev.
1 μM 12,52 12,00 16,30 11,99 13,20 2,08
3 μM 11,48 11,40 12,62 9,82 11,33 1,15
10 μM 10,03 10,85 12,47 10,77 11,03 1,03
20 μM 11,51 8,89 9,76 9,03 9,80 1,20
30 μM 13,04 10,83 12,95 12,23 12,26 1,02
Table 35: Production of ROS in HepG2 cells exposed to MTBITC for 3 h (% of control)
Test 1 Test 2 Test 3 Test 4 mean std. dev.
1 μM 9,01 11,68 14,40 11,71 11,70 2,20
3 μM 9,97 10,12 13,42 11,41 11,23 1,60
10 μM 9,40 10,79 13,63 12,71 11,63 1,90
20 μM 13,75 10,80 13,31 14,92 13,20 1,74
30 μM 17,61 16,94 20,25 19,60 18,60 1,58
Table 36: Production of ROS in HepG2 cells exposed to MTBITC for 6 h (% of control)
Test 1 Test 2 Test 3 Test 4 mean std. dev.
1 μM 3,95 5,12 5,58 4,89 4,89 0,69
3 μM 4,58 5,19 6,03 5,12 5,23 0,60
10 μM 7,55 8,23 8,35 9,06 8,30 0,62
20 μM 9,17 8,25 10,10 9,44 9,24 0,77
30 μM 10,68 11,38 11,81 11,61 11,37 0,49
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Table 37: DNA damage in HepG2 cells after 1 h-treatment with 20 μM MTBITC
SC 20 μM + control
Test 1 0,91 1,91 2,55
Test 2 0,89 2,12 2,52
Test 3 0,77 2,34 2,80
mean 0,86 2,12 2,62
std. dev. 0,07 0,22 0,16
Table 38: Expression of p53 in HepG2 cells after Exposure to MTBITC for 1 h (% of control)
3 μM 10 μM 20 μM 30 μM
Test 1 109,66 143,21 279,45 147,86
Test 2 142,93 229,27 310,44 229,57
Test 3 144,86 229,81 375,06 160,73
mean 132,48 200,76 321,65 179,39
std. dev. 19,79 49,84 48,78 43,93
Table 39: Expression of p53 in HepG2 cells after Exposure to MTBITC for 3 h (% of control)
3 μM 10 μM 20 μM 30 μM
Test 1 106,74 98,38 57,62 53,09
Test 2 103,37 74,4 31,11 24,09
Test 3 102,95 78,73 43,2 46,72
mean 104,35 83,84 43,98 41,30
std. dev. 2,08 12,78 13,27 15,24
Table 40: Expression of p53 in HepG2 cells after Exposure to MTBITC for 6 h (% of control)
3 μM 10 μM 20 μM 30 μM
Test 1 95,52 106,9 215,54 96,44
Test 2 115,91 114,71 146,47 87,24
Test 3 119,44 138,61 209,17 73,68
mean 110,29 120,07 190,39 85,79
std. dev. 12,91 16,52 38,17 11,45
Table 41: Expression of p53 in HepG2 cells after Exposure to MTBITC for 24 h (% of control)
3 μM 10 μM 20 μM 30 μM
Test 1 95,08 86,47 44,64 59,73
Test 2 96,71 81,57 80,59 61,18
Test 3 90,89 105,47 74,96 40,76
mean 94,23 91,17 66,73 53,89
std. dev. 3,00 12,62 19,34 11,39
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Table 42: Expression of p63 in HepG2 cells after Exposure to MTBITC for the indicated time points 
(% of control)
1 h 3 h 6 h 24 h 48 h
Test 1 127,09 142,79 170,60 444,85 543,78
Test 2 106,05 59,81 237,99 494,66 502,85
Test 3 173,08 92,10 228,40 417,42 513,08
mean 135,40 98,23 212,33 452,31 519,90
std. dev. 34,28 41,83 36,45 39,16 21,30
Table 43: Expression of MDM2 in HepG2 cells after Exposure to 20 μM MTBITC for the indicated 
time points (% of control)
Test 1 Test 2 Test 3 mean std. dev.
1 h 1 0 0 0 0,23
3 h 7 6 6 6 0,58
6 h 174 128 197 167 35,29
24 h 941 860 886 895 41,08
48 h 679 582 729 663 74,96
Table 44: Expression of hTERT in HepG2 cells after Exposure to 20 μM MTBITC for the indicated 
time points (% of control)
Test 1 Test 2 Test 3 mean std. dev.
1 h 89,2 99,46 103,34 97,34 7,30
3 h 75,6 69,92 88,57 78,04 9,55
6 h 70,9 53,17 66,91 63,67 9,31
24 h 51,8 61,98 44,58 52,79 8,74
48 h 61,16 70,19 50,89 60,75 9,66
Table 46: Telomerase activity of HepG2 cells after 20 μM MTBITC-treatment for the indicated time 
points (% of control)
6 h 24 h 48 h 72 h + control
Test 1 97,84 92,10 83,61 50,87 11,56
Test 2 99,20 89,37 76,82 45,36 12,44
Test 3 102,63 91,96 75,24 58,75 5,80
mean 99,89 91,14 78,56 51,66 9,93
std. dev. 2,47 1,53 4,45 6,73 3,61
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Table 47: Telomerase activity of HepG2 cells after exposure to TMPyP4 for 24 h (% of control)
100 μM 200 μM 300 μM
Test 1 76,16 41,87 11,56
Test 2 92,19 24,91 12,44
Test 3 92,23 33,03 5,80
mean 86,86 33,27 9,93
std. dev. 9,27 8,48 3,61
Table 48: Expression of HSP90 in HepG2 cells after Exposure to 20 μM MTBITC for the indicated 
time points (% of control)
Test 1 Test 2 mean std. dev.
1 h 147,74 164,55 156,15 11,88
3 h 202,16 239,35 220,76 26,30
6 h 282,20 277,79 279,99 3,11
24 h 322,73 292,90 307,82 21,09
48 h 472,37 416,89 444,63 39,23
Table 49: Expression of HSP70 in HepG2 cells after Exposure to 20 μM MTBITC for the indicated 
time points (% of control)
Test 1 Test 2 Test 3 mean std. dev.
1 h 48,42 62,82 87,39 66,21 19,70
3 h 71,42 83,73 68,95 74,70 7,92
6 h 192,62 92,33 115,52 133,49 52,51
24 h 222,06 280,99 298,42 267,16 40,02
48 h 421,12 219,65 330,65 323,81 100,91
Table 50: Determination of the telomere length of HepG2 cells after exposure to 20 μM MTBITC for the 
indicated time points
SC 1 h 6 h 24 h 48 h 
Test 1 22,79 22,45 24,31 21,47 22,54
Test 2 23,02 22,25 23,58 25,98 23,5
Test 3 21,81 21,56 22,28 20,45 28,17
mean 22,54 22,09 23,39 22,63 24,74
std. dev. 0,64 0,47 1,03 2,94 3,01
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Table 51: Degradation kinetic of MTBITC in culture medium containing 1 x 106 HepG2 cells (% of 
control)
Time (min.) Test 1 Test 2 Test 3 mean std. dev.
30 65,1 65,42 66,11 65,54 0,52
60 44,82 53,88 53,46 50,72 5,11
180 36,36 34,23 33,48 34,69 1,49
360 28,68 29,57 16,92 25,06 7,06
1440 0,00 0,00 0,00 0,00 0,00
Table 52: Degradation kinetic of MTBITC in culture medium w/o cells (% of control)
Time (min.) Test 1 Test 2 mean std. dev.
30 90,25 70,17 80,21 14,20
60 73,21 55,24 64,23 12,71
180 45,83 46,6 46,22 0,54
360 34,88 27,75 31,32 5,04
1440 0,00 0,00 0,00 0,00
Table 53: Degradation kinetic of MTBITC in destilled water with gas exchange (% of control)
Time (min.) Test 1 Test 2 mean std. dev.
30 83,3 68,5 75,90 10,47
60 69,86 56,55 63,21 9,41
180 41,87 51,02 46,45 6,47
360 36,1 32,05 34,08 2,86
1440 28,35 23,24 25,80 3,61
Table 54: Degradation kinetic of MTBITC in destilled water w/o gas exchange (% of control)
Time (min.) Test 1 Test 2 Test 3 mean std. dev.
30 66,07 67,42 77,45 70,31 6,22
60 57,72 60,06 65,23 61,00 3,84
180 49,77 54,3 53,05 52,37 2,34
360 45,87 47,38 52,85 48,70 3,67
1440 29,98 35,27 40,79 35,35 5,41
Table 55: Determination of the "point of no return" in HepG2 cells after exposure to 20 μM 
MTBITC (% of control)
1 h 6 h 24 h
Test 1 98,73 5,97 4,28
Test 2 76,39 3,99 2,28
Test 3 89,57 6,07 4,01
mean 88,23 5,34 3,52
std. dev. 11,23 1,17 1,09
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